

=> d his

(FILE 'HOME' ENTERED AT 11:46:54 ON 02 JUL 2007)

L1 FILE 'REGISTRY' ENTERED AT 11:47:00 ON 02 JUL 2007  
L2 STRUCTURE UPLOADED  
1270 S L1 SSS FULL  
SAV TEM BRD530482/A L2

FILE 'STNGUIDE' ENTERED AT 11:48:17 ON 02 JUL 2007

L3 FILE 'REGISTRY' ENTERED AT 11:56:39 ON 02 JUL 2007  
L4 STRUCTURE UPLOADED  
50 S L3 SAM SUB=L2  
L5 1125 S L3 SSS FULL SUB=L2

FILE 'STNGUIDE' ENTERED AT 11:57:29 ON 02 JUL 2007

FILE 'REGISTRY' ENTERED AT 11:57:53 ON 02 JUL 2007

FILE 'REGISTRY' ENTERED AT 11:58:02 ON 02 JUL 2007  
SAV TEM L5 BR2530482/A

L6 FILE 'CAPLUS' ENTERED AT 11:58:18 ON 02 JUL 2007  
102 S L5

FILE 'STNGUIDE' ENTERED AT 11:58:24 ON 02 JUL 2007

FILE 'REGISTRY' ENTERED AT 11:59:13 ON 02 JUL 2007

FILE 'STNGUIDE' ENTERED AT 11:59:46 ON 02 JUL 2007

L7 FILE 'REGISTRY' ENTERED AT 12:04:37 ON 02 JUL 2007  
L8 STRUCTURE UPLOADED  
43 S L7 SAM SUB=L5  
L9 739 S L7 SSS FULL SUB=L5  
SAV TEM L9 BR3530482/A

L10 FILE 'CAPLUS' ENTERED AT 12:05:48 ON 02 JUL 2007  
71 S L9

FILE 'STNGUIDE' ENTERED AT 12:05:58 ON 02 JUL 2007

FILE 'CAPLUS' ENTERED AT 13:06:57 ON 02 JUL 2007

FILE 'REGISTRY' ENTERED AT 13:06:59 ON 02 JUL 2007

L11 FILE 'CAPLUS' ENTERED AT 13:08:00 ON 02 JUL 2007  
L12 0 S US2005-530482  
L13 1 S WO2003-JP12985/AP  
70 S L10 NOT L12

FILE 'STNGUIDE' ENTERED AT 14:20:18 ON 02 JUL 2007

L14 FILE 'REGISTRY' ENTERED AT 14:28:41 ON 02 JUL 2007  
1 S 654663-70-4

FILE 'STNGUIDE' ENTERED AT 14:29:23 ON 02 JUL 2007

L15 FILE 'REGISTRY' ENTERED AT 14:30:21 ON 02 JUL 2007  
1 S L14


FILE 'REGISTRY' ENTERED AT 14:31:07 ON 02 JUL 2007

L16 1 S 676481-96-2  
FILE 'CAPLUS' ENTERED AT 14:31:24 ON 02 JUL 2007  
L17 1 S L16  
FILE 'REGISTRY' ENTERED AT 14:31:37 ON 02 JUL 2007  
L18 1 S 387829-06-3  
FILE 'CAPLUS' ENTERED AT 14:31:51 ON 02 JUL 2007  
L19 2 S L18  
FILE 'REGISTRY' ENTERED AT 14:32:34 ON 02 JUL 2007  
L20 1 S 508167-98-4  
FILE 'CAPLUS' ENTERED AT 14:32:45 ON 02 JUL 2007  
L21 2 S L20  
FILE 'REGISTRY' ENTERED AT 14:33:16 ON 02 JUL 2007  
L22 1 S 183113-24-8  
FILE 'CAPLUS' ENTERED AT 14:33:35 ON 02 JUL 2007  
L23 6 S L22  
S 76644-54-7/REG#  
FILE 'REGISTRY' ENTERED AT 14:34:52 ON 02 JUL 2007  
L24 1 S 76644-54-7/RN  
FILE 'CAPLUS' ENTERED AT 14:34:53 ON 02 JUL 2007  
L25 9 S L24  
FILE 'CAPLUS' ENTERED AT 14:34:59 ON 02 JUL 2007  
FILE 'REGISTRY' ENTERED AT 14:35:36 ON 02 JUL 2007  
L26 1 S 76644-54-7  
FILE 'CAPLUS' ENTERED AT 14:35:53 ON 02 JUL 2007  
L27 9 S L26  
FILE 'STNGUIDE' ENTERED AT 14:37:22 ON 02 JUL 2007  
FILE 'REGISTRY' ENTERED AT 15:23:16 ON 02 JUL 2007  
L28 STRUCTURE UPLOADED  
L29 0 S L28 SSS FULL SUB=L9  
FILE 'STNGUIDE' ENTERED AT 15:24:13 ON 02 JUL 2007  
FILE 'REGISTRY' ENTERED AT 15:28:10 ON 02 JUL 2007  
L30 STRUCTURE UPLOADED  
L31 95 S L30 SSS FULL SUB=L9  
FILE 'CAPLUS' ENTERED AT 15:28:51 ON 02 JUL 2007  
L32 19 S L31  
L33 18 S L32 NOT L12  
FILE 'STNGUIDE' ENTERED AT 15:30:02 ON 02 JUL 2007  
FILE 'REGISTRY' ENTERED AT 15:32:06 ON 02 JUL 2007  
L34 STRUCTURE UPLOADED  
L35 0 S L34 SSS FULL SUB=L9  
FILE 'STNGUIDE' ENTERED AT 15:32:59 ON 02 JUL 2007  
FILE 'REGISTRY' ENTERED AT 15:34:15 ON 02 JUL 2007

=> d 130

L30 HAS NO ANSWERS

L30 STR



Structure attributes must be viewed using STN Express query preparation.

L33 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:61833 CAPLUS

DN 146:156276

TI Celullar cholesterol absorption modifiers

IN Gardiner, Elisabeth M.; Duron, Wergio G.; Massari, Mark E.; Severance, Daniel L.; Semple, Joseph E.; Smith, Nicholas D.

PA Kalypsys, Inc., USA

SO PCT Int. Appl., 76pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007008529	A2	20070118	WO 2006-US26197	20060706
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-697687P	P	20050708		
	US 2005-727652P	P	20051017		
	US 2006-781972P	P	20060313		
OS	MARPAT 146:156276				
AB	The present invention relates to compds. and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of cholesterol-related diseases, such as atherosclerosis (Markush structures given). Fifty-two novel aromatic diaza derivs. that prevent cholesterol absorption by inhibition of NPC1L1 were prepared and their antihypercholesterolemic activity is shown.				
IT	330590-00-6P 339242-35-2P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(celullar cholesterol absorption modifiers)				
RN	330590-00-6 CAPLUS				
CN	Benzoic acid, 4-hydroxy-, 2-[[1-(3-chlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (CA INDEX NAME)				





PAGE 1-A



PAGE 2-A




RN 339242-35-2 CAPLUS  
CN Benzoic acid, 2-hydroxy-, 2-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (CA INDEX NAME)



L33 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1098053 CAPLUS  
 DN 145:438636  
 TI Novel compounds for treatment of cancer and disorders associated with  
 angiogenesis function and their preparation and pharmaceutical  
 compositions  
 IN Neamati, Nouri  
 PA USA  
 SO U.S. Pat. Appl. Publ., 74pp., Cont.-in-part of U.S. Ser. No. 27,465.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2006235034	A1	20061019	US 2005-265593	20051101
	US 2006142294	A1	20060629	US 2004-27465	20041229
PRAI	US 2004-624253P	P	20041101		
	US 2004-27465	A2	20041229		
GI					



I

AB Novel compds. for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compds., pharmaceutical compns. and packaged products containing the compds., a method of using these mols. to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression. Example compound I was prepared by condensation of 7-fluoro-4-hydrazinopyrrolo[1,2-a]quinoxaline with 2-pyrazinecarboxylic acid. All the invention compds. were evaluated for their antitumor and antiangiogenesis activity. Compound I showed good activity against various genes.


IT 331238-74-5 908254-85-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of aryl hydrazides for treatment of cancer and disorders associated with angiogenesis function)


RN 331238-74-5 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)



RN 908254-85-3 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)methyl]hydrazide (9CI) (CA INDEX NAME)



L33 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:885044 CAPLUS

DN 145:285109

TI Novel compounds for treatment of cancer and disorders associated with angiogenesis function

IN Neamati, Nouri; Garofalo, Antonio

PA University of Southern California, USA

SO PCT Int. Appl., 127pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006091246	A1	20060831	WO 2005-US39687	20051101
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006142294	A1	20060629	US 2004-27465	20041229
PRAI	US 2004-624253P	P	20041101		
	US 2004-27465	A	20041229		
OS	MARPAT 145:285109				
GI					



AB Disclosed are novel compds. I [X = CH or N; Z = O or S; R and R1 independently = alkyl, halo, acetyl, O-alkyl, or N-alkyl; Y = alkyl, heteroaryl, sugar, etc.] for treatment of cancer and disorders associated with angiogenesis function. Methods for preparing a subset of invention compds. are presented. Thus, e.g., II was prepd. by reaction of 4-hydrazino-7,8-dimethylpyrrolo[1,2-a]quinoxaline with 2-pyrazinecarboxylic acid. Addnl., pharmacophore anal. of a 10,000 compound database of reported and patented integrase inhibitors led to acquiring numerous analogs of salicylhydrazides from com. sources and these compds. were then subjected to cytotoxicity assays. Also disclosed are a method of preparing the compds., pharmaceutical compns. and packaged products containing

the compds., a method of using these mols. to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.


IT 331238-74-5 908254-85-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel compound for treatment of cancer and disorders associated with angiogenesis function)


RN 331238-74-5 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)



RN 908254-85-3 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)methyl]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:15425 CAPLUS

DN 144:245927

TI Synthesis and structural characterization of three hydrogen-bonding connected supramolecular complexes of nickel, zinc and copper with 1,3-diphenyl-4-(salicylhydrazide acetyl)pyrazolone-5 and 2,2'-bipyridine

AU Hu, Xin; Zhang, Li; Liu, Lang; Liu, Guangfei; Jia, Diansheng; Xu, Guancheng  
CS Institute of Applied Chemistry, Xinjiang University, Urumqi, Xinjiang Province, 830046, Peop. Rep. China

SO Inorganica Chimica Acta (2006), 359(2), 633-641  
CODEN: ICHAA3; ISSN: 0020-1693


PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 144:245927

GI




AB A new set of supramol. complexes, [Ni(DPAP-SHZ)(2,2'-bipy)CH<sub>3</sub>OH] (1), [Zn(DPAP-SHZ)(2,2'-bipy)CH<sub>3</sub>OH] (2) and [Cu(DPAP-SHZ)(2,2'-bipy)]·2CH<sub>2</sub>Cl<sub>2</sub> (3) (H<sub>2</sub>DPAP-SHZ = 1,3-diphenyl-4-(salicylhydrazide acetyl)-pyrazolone-5 (I), 2,2'-bipy = 2,2'-bipyridine) were synthesized and characterized by elemental anal., TG-DTA, IR spectroscopy and x-ray crystallog. The x-ray diffraction analyses of the complexes show that the Ni(II) ion and Zn(II) ion centers are six-coordinated while the Cu(II) ion center is five-coordinated. The three supramol. complexes contain the same ligands, DPAP-SHZ and 2,2'-bipy. However, their hydrogen bonds are significantly different, and this variation apparently is responsible for the dissimilar structures of the three supramol. complexes.

IT 876610-67-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of nickel, zinc and copper diphenyl(salicylhydrazide acetyl)pyrazolone bipyridine complexes)

RN 876610-67-2 CAPLUS


CN Benzoic acid, 2-hydroxy-, [1-(4,5-dihydro-5-oxo-1,3-diphenyl-1H-pyrazol-4-yl)ethylidene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1069402 CAPLUS  
 DN 144:331321  
 TI Crystal structure of a novel compound. 1-Phenyl-3-methyl-4-[2-(salicylhydrazido)propylidene]-5-pyrazolone  
 AU Chai, Hui; Liu, Guang-Fei; Liu, Lang; Jia, Dian-Zeng  
 CS Institute of Applied Chemistry, Xinjiang University, Urumqi, Xinjiang, 830046, Peop. Rep. China  
 SO Jiegou Huaxue (2005), 24(9), 1091-1095  
 CODEN: JHUADF; ISSN: 0254-5861  
 PB Jiegou Huaxue Bianji Weiyuanhui

DT Journal  
 LA English  
 OS CASREACT 144:331321  
 AB A novel compound 1-phenyl-3-methyl-4-[2-(salicylhydrazido)propylidene]-5-pyrazolone was synthesized and characterized by elemental anal., IR, <sup>1</sup>H NMR and single-crystal x-ray diffraction. The x-ray diffraction reveals that the compound is of orthorhombic, space group Pbca with a = 16.132(5), b = 10.113(3), c = 23.143(7) Å, V = 3776(2) Å<sup>3</sup>, Z = 8, C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>, Mr = 364.40, D<sub>c</sub> = 1.282 g/cm<sup>3</sup>, F(000) = 1536, μ(MoKα) = 0.089 mm<sup>-1</sup>, S = 0.992, R = 0.0578 and wR = 0.1362 for 1871 observed reflections with I > 2σ(I). In the crystal, the compound possesses two C = O bonds and exists in the NH-form' other than NH-form.  
 IT 331668-46-3P  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and crystal structure of phenyl-methyl(salicylhydrazido)propylidene-pyrazolone)  
 RN 331668-46-3 CAPLUS  
 CN Benzoic acid, 2-hydroxy-, 2-[1-(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)propyl]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:610650 CAPLUS  
 DN 143:318545  
 TI Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines  
 AU Plasencia, Carmen; Dayam, Raveendra; Wang, Qingcai; Pinski, Jacek; Burke, Terrence R., Jr.; Quinn, David I.; Neamati, Nouri  
 CS Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California, CA, USA  
 SO Molecular Cancer Therapeutics (2005), 4(7), 1105-1113  
 CODEN: MCTOCF; ISSN: 1535-7163  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 AB We discovered a series of salicylhydrazide class of compds. with remarkable anticancer activity against a panel of hormone receptor-pos. and -neg. cell lines. In the present study, we evaluated the in vitro activity of SC21 and SC23 against a range of human tumor cell types and the in vivo efficacy of compound SC21 in a PC3 human prostate cancer xenograft model in mice. We also determined the effects of SC21 on cell cycle regulation and apoptosis. Our in vitro results show that salicylhydrazides are highly potent compds. effective in both hormone




receptor-pos. and -neg. cancer cells. SC21 induced apoptosis and blocked the cell cycle in G0/G1 or S phase, depending on the cell lines used and irresp. of p53, p21, pRb, and p16 status. SC21 effectively reduced the tumor growth in mice without apparent toxicity. Although the mechanism of action of SC21 is not completely elucidated, the effect on cell cycle, the induction of apoptosis and the activity against a panel of tumor cell lines of different origins prompted us to carry out an in-depth preclin. evaluation of SC21.

IT 331238-74-5

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (discovery and preclin. evaluation of salicylhydrazides in hormone-dependent and -independent cancer cell lines)

RN 331238-74-5 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 7 OF 18 CAPLUS. COPYRIGHT 2007 ACS on STN

AN 2005:421924 CAPLUS

DN 143:431451

TI Solid-state and liquid-state syntheses and characterization of Cu(II) complexes of pyrazolone derivatives

AU Feng, Ting; Liu, Lang; Zhang, Li; Jia, Dian-Zeng

CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop. Rep. China

SO Yingyong Huaxue (2005), 22(4), 372-376

CODEN: YIHUED; ISSN: 1000-0518

PB Kexue Chubanshe

DT Journal

LA Chinese

OS CASREACT 143:431451


AB Several Cu(II) complexes were synthesized by solid-state reaction and liquid-state reaction of pyrazolone derivs. with cupric acetate, resp., and characterized by elemental anal., IR, TG-DTA and XRD techniques. The results show that the solid-state reaction and liquid-state reaction lead to different products. The mol. formula of the liquid-state reaction products are M2L2·nH2O (n = 0, 1) and those of the solid-state reaction products are M(H2L)·2OAc·nH2O (n = 1, 2).

IT 387829-06-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(solid-state and liquid-state syntheses and characterization of Cu(II) complexes of pyrazolone derivs.)


RN 387829-06-3 CAPLUS  
CN Benzoic acid, 2-hydroxy-, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



L33 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:754447 CAPLUS  
DN 140:303580  
TI Synthesis, characterization and bacteriostatic activity of compound derived from PMTFP and salicylic hydrazide  
AU Zhang, Shu-ming; Jia, Yong-jin; Wang, Jin-ling; Miao, Fang-ming  
CS College of Chemistry and Life Science, Tianjin Normal University, Tianjin, 300074, Peop. Rep. China  
SO Tianjin Shifan Daxue Xuebao, Ziran Kexueban (2003), 23(2), 4-6  
CODEN: TSDXAD; ISSN: 1671-1114  
PB Tianjin Shifan Daxue Xuebao, Ziran Kexueban Bianjibu  
DT Journal  
LA Chinese  
OS CASREACT 140:303580  
AB A Schiff base derived from 1-phenyl-3-methyl-4-trifluoroacetyl-5-pyrazolone (PMTFP) and salicylic hydrazide have been synthesized and characterized by IR and UV. This compound showed good inhibiting activities for both Gram-pos. bacteria-Staphylococcus aureus and Gram-neg. bacteria-Escherichia coli.  
IT 676481-96-2P  
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(synthesis and bacteriostatic activities of Schiff base from PMTFP and salicylic hydrazide)  
RN 676481-96-2 CAPLUS  
CN Benzoic acid, 2-hydroxy-, [1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)-2,2,2-trifluoroethylidene]hydrazide (9CI) (CA INDEX NAME)



L33 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:483572 CAPLUS  
 DN 139:245944  
 TI Synthesis and crystal structure of supramolecular compound of  
 4-(a'-hydroxybenzoylhydrazinyl)benzal/ethylidene-5-methyl-2-phenyl-2,4-  
 dihydropyrazol-3-one  
 AU Liu, Lang; Ji, Ya-Li; Jia, Dian-Zeng; Yu, Kai-Bei  
 CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop.  
 Rep. China  
 SO Huaxue Xuebao (2003), 61(6), 893-900  
 CODEN: HHHPA4; ISSN: 0567-7351  
 PB Kexue Chubanshe  
 DT Journal  
 LA Chinese  
 OS CASREACT 139:245944  
 GI



I

AB The synthesis and crystal structure of title compds. I (R = Ph, Me) are  
 presented in this paper. The crystal structures were determined by X-ray  
 single crystal diffraction study. Crystal structure of I (R = Ph) belongs  
 to monoclinic system with space group C2/c. The unit cell parameters are  
 $a = 1.4201(2)$  nm,  $b = 1.65542(2)$  nm,  $c = 1.8455(3)$  nm,  $\beta = 10132(1)^\circ$ ,  
 $V = 4.2541(10)$  nm<sup>3</sup>,  $Z = 8$ ,  $D_c = 1.344$  g/cm<sup>3</sup>,  $\mu = 0.094$  mm<sup>-1</sup>,  
 $F(000) = 1808$ ,  $R = 0.0442$ ,  $wR = 0.1037$ . The water mols. bridge the  
 adjacent stacks by the hydrogen bonds leading to the formation of  
 supramol. compound with two-dimensional network structure along the ac  
 side. The crystal structure of II (R = Me) belongs to triclinic system  
 with space group P.hivin.1. The unit cell parameters are  $a = 1.2120(2)$   
 nm,  $b = 1.2223(2)$  nm,  $c = 1.4159(3)$  nm,  $\alpha = 70.38(1)^\circ$ ,  $\beta = 74.91(1)^\circ$ ,  
 $\gamma = 63.64(1)^\circ$ ,  $V = 1.7549(5)$  nm<sup>3</sup>,  $Z = 4$ ,  $D_c = 1.326$  g/cm<sup>3</sup>,  
 $\mu = 0.092$  mm<sup>-1</sup>,  $F(000) = 736$ ,  $R = 0.0436$ ,  $wR = 0.1076$ . The  
 supramol. with one dimensional chain structure was formed through  
 hydrogen bonds along the a axis. The mols. piled the layered

structure along the b axis due to intermol. interactions.


IT 599166-78-6P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis and crystal structure of supramol. compound of  
hydroxybenzoylhydrazinylbenzalidenemethylphenyldihydropyrazolone)

RN 599166-78-6 CAPLUS

CN Benzoic acid, 2-hydroxy-, (2E)-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 599166-81-1P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis and crystal structure of supramol. compound of  
hydroxybenzoylhydrazinylethylidenemethylphenyldihydropyrazolone)

RN 599166-81-1 CAPLUS

CN Benzoic acid, 2-hydroxy-, (2E)-[1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)ethylidene]hydrazide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L33 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:259127 CAPLUS

DN 139:62054

TI Synthesis, characterization and crystal structure of mixed-ligand complex  
[Ni(PMBP-sal)(py)]

AU Ji, Ya-Li; Liu, Lang; Jia, Dian-Zeng; Yu, Kai-Bei

CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop.  
Rep. China

SO Wuji Huaxue Xuebao (2003), 19(4), 345-349

CODEN: WHUXEO; ISSN: 1001-4861

PB Wuji Huaxue Xuebao Bianjibu

DT Journal


LA English

OS CASREACT 139:62054


AB A new mixed-ligand Ni(II) complex, [Ni(PMBP-sal)(py)], (PMBP-sal =  
1-phenyl-3-methyl-4-benzylidene-pyrazolone-5 salicylhydrazide; py =  
pyridine), was synthesized and characterized by elemental anal., IR  
spectrum, UV-visible spectrum, cyclic voltammogram and single crystal

x-ray diffraction. It crystallizes in the monoclinic system, space group P21/c. The lattice parameters are: a 1.3544(3), b 1.7225(5), c 1.0937(2) nm,  $\beta$  102.57(2)°, V = 2.4904(10) nm<sup>3</sup>,  $d_c$  = 1.462 g m<sup>-3</sup>, Z = 4. The coordination geometry around Ni(II) in the ternary mixed-ligand complex is slightly distorted four-coordinated square-planar geometry, in which the primary ligand PMBP-sal participates in coordination with ONO donor atoms and the secondary ligand pyridine is N-bonded.

IT 387829-06-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (for preparation of nickel benzylidenepyrazolone salicylhydrazone complex)  
 RN 387829-06-3 CAPLUS  
 CN Benzoic acid, 2-hydroxy-, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



L33 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2000:431992 CAPLUS  
 DN 133:237910  
 TI Synthesis of novel benzoquinone and hydroquinone derivatives bearing different heterocyclic systems as potential antimicrobial agents  
 AU Chaaban, I.; Bekhit, A. A.; Abdet-Ghany, Y. S.  
 CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Alexandria, Alexandria, Egypt  
 SO Egyptian Journal of Pharmaceutical Sciences (1999), Volume Date 1998, 39(1-3), 91-107  
 CODEN: EJPSBZ; ISSN: 0301-5068  
 PB National Information and Documentation Centre  
 DT Journal  
 LA English  
 AB Hydroquinonecarbonyl and benzoquinonecarbonyl derivs. of aminothiazolidinones and pyrazolidinediones were prepared. Th compds. showed good to excellent antibacterial and antifungal activity with the hydroquinones showing better activity than the benzoquinones.  
 IT 131624-94-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (benzoquinone and hydroquinonecarbonyl derivs. of aminothiazolidinones and pyrazolidinediones as fungicides and bactericides)  
 RN 131624-94-7 CAPLUS  
 CN Benzoic acid, 2,5-dihydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:397267 CAPLUS

DN 131:193889

TI Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target

AU Sausville, Edward A.; Zaharevitz, Daniel; Gussio, Robert; Meijer, Laurent; Louarn-Leost, Maryse; Kunick, Conrad; Schultz, Robert; Lahusen, Tyler; Headlee, Donna; Stinson, Sherman; Arbuck, Susan G.; Senderowicz, Adrian

CS Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA

SO Pharmacology & Therapeutics (1999), 82(2-3), 285-292

CODEN: PHTHDT; ISSN: 0163-7258

PB Elsevier Science Inc.

DT Journal

LA English

AB Cyclin-dependent kinases (CDKs) have been recognized as key regulators of cell cycle progression. Alteration and deregulation of CDK activity are pathogenic hallmarks of neoplasia. Therefore, inhibitors or modulators would be of interest to explore as novel therapeutic agents in cancer, as well as other hyperproliferative disorders. Flavopiridol is a semisynthetic flavonoid that emerged from an empirical screening program as a potent antiproliferative agent that mechanistic studies demonstrated to directly inhibit CDKs 1, 2, and 4 as a competitive ATP site antagonist. Initial clin. trials have shown that concns. that inhibit cell proliferation and CDK activity in vitro can be safely achieved in humans, and addnl. clin. trials will establish its clin. potential. To address the need for addnl. chemotypes that may serve as lead structures for drugs that would not have the toxicities associated with flavopiridol, compds. with a similar pattern of cell growth inhibitory activity in the National Cancer Institute's in vitro anticancer drug screen have been recognized by the computer-assisted pattern recognition algorithm COMPARE and then screened for anti-CDK activity in a biochem. screen. The benzodiazepine derivative NSC 664704 (7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one) was revealed by that approach as a moderately potent (IC<sub>50</sub> 0.4 μM) inhibitor of CDK2, which in initial expts. shows evidence of causing cell cycle redistribution in living cells. NSC 664704 is, therefore, a candidate for further structural optimization, guided in part by understanding of the ATP-binding site in CDK2. This approach represents one way of combining empirical screening information with structure-based design to derive novel candidate therapeutic agents directed against an

important cellular target.


IT 101868-30-8, NSC 651704

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target)

RN 101868-30-8 CAPLUS

CN Benzoic acid, 3,5-dibromo-2-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:375841 CAPLUS

DN 127:75044

TI Oxovanadium binuclear (IV) Schiff base complexes derived from aroyl hydrazones having subnormal magnetic moments

AU Rao, Sumita N.; Mishra, D. D.; Maurya, R. C.; Rao, N. Nageswara

CS Dep. Post Grad. Studies and Res. Chem., Rani Durgavati Vishwavidyalaya, Jabalpur, 482 001, India

SO Polyhedron (1997), 16(11), 1825-1829

CODEN: PLYHDE; ISSN: 0277-5387

PB Elsevier

DT Journal

LA English

AB Oxovanadium(IV) complexes of aroyl hydrazone Schiff bases, viz. salicyloyl, nicotinoyl and benzoyl hydrazones, were synthesized and characterized by elemental anal., spectroscopy (IR and UV-visible) methods, magnetic susceptibility, EPR measurements, molar conductance and cyclic voltammetry studies. The room-temperature magnetic moments of the complexes are in the range 0.97-1.03  $\mu_B$  and are indicative of the presence of antiferromagnetic exchange. A binuclear structure is proposed for the complexes.

IT 191219-03-1P 191219-06-4P


RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(for preparation of vanadyl benzoyl- or nitrobenzoyl(methyl)(phenyl)pyrazolo ne aroyl hydrazone Schiff base complexes)

RN 191219-03-1 CAPLUS


CN Benzoic acid, 2-hydroxy-, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-

yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



RN 191219-06-4 CAPLUS

CN Benzoic acid, 2-hydroxy-, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)(4-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN.

AN 1991:61995 CAPLUS

DN 114:61995

TI Potential antibacterial agents. Part II. Synthesis of substituted N-antipyrinyl methylenebenzohydrazides and 2-antipyrinyl-5-aryl-1,3,4-oxadiazoles


AU Begum, Tahira; Hussain, Shaheen A.; Sultana, Naheed; Murtaza, Najma; Qureshi, Izhar H.

CS PCSIR Lab. Complex, Karachi, Pak.

SO Pakistan Journal of Scientific and Industrial Research (1989), 32(11), 722-5



DT Journal  
 LA English  
 OS CASREACT 114:61995  
 GI




AB Condensation of 4-formylantipyrine with substituted benzohydrazides  $H_2NNHCOR$  ( $R = Ph$ , substituted  $Ph$ ) afforded substituted antipyrinylmethylenbenzohydrazides I. On treatment with bromine-acetic acid-sodium acetate, I ( $R = Ph$ , 4-MeC<sub>6</sub>H<sub>4</sub>, 4-MeOC<sub>6</sub>H<sub>4</sub>, 4-ClC<sub>6</sub>H<sub>4</sub>) readily cyclized to 2-antipyrinyl-5-aryl-1,3,4-oxadiazoles II, whereas I ( $R = 2-HOC_6H_4$ ), under similar treatment furnished the hitherto unreported dibromo compound III. Antibacterial activity of the compds synthesized was also evaluated. They did not show any significant activity.

IT 102017-61-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and bromination of)

RN 102017-61-8 CAPLUS


CN Benzoic acid, 2-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




L33 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1991:61992 CAPLUS  
 DN 114:61992  
 TI Synthesis of substituted 2,3-dihydro-1,3,4-oxadiazole derivatives  
 containing a substituted pyrazole moiety as potential anti-inflammatory  
 agents  
 AU Farghaly, Ahmed M.; Chaaban, Ibrahim; El-Khawass, El-Sayed M.; Fahmy,  
 Salwa M.  
 CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt  
 SO Alexandria Journal of Pharmaceutical Sciences (1989), 3(2), 158-60  
 CODEN: AJPSES; ISSN: 1110-1792  
 DT Journal  
 LA English  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Pyrazolecarboxaldehyde benzoylhydrazones I and II (R = H, OH; R1 = H, OH,  
 OMe, NH2, R2 = H, OH) were prepared by the condensation of the corresponding  
 pyrazolecarboxaldehydes with 2,4,5-RR1R2C6H2CONHNH2. Treating I with Ac2O  
 gave pyrazolyloxadiazoles III (R = H, OAc, R1 = H, OAc, OMe, NHAc, R2 = H,  
 OAc).  
 IT 102017-61-8P 131624-93-6P 131624-94-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 102017-61-8 CAPLUS  
 CN Benzoic acid, 2-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-  
 pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 131624-93-6 CAPLUS  
 CN Benzoic acid, 4-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-  
 pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 131624-94-7 CAPLUS  
 CN Benzoic acid, 2,5-dihydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



L33 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1976:510096 CAPLUS  
 DN 85:110096  
 TI 1:1 Azomethine-metal complex dyes  
 IN L'Eplattenier, Francois; Vuitel, Laurent  
 PA Ciba-Geigy A.-G., Switz.  
 SO Ger. Offen., 24 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2556473	A1	19760701	DE 1975-2556473	19751215

CH 606284	A5	19781031	CH 1974-16810	19741217
CA 1070677	A1	19800129	CA 1975-241772	19751215
FR 2295092	A1	19760716	FR 1975-38423	19751216
JP 51088539	A	19760803	JP 1975-151176	19751217
US 4144258	A	19790313	US 1977-840707	19771011
PRAI CH 1974-16810	A	19741217		
US 1975-640373	A3	19751212		
GI	For diagram(s), see printed CA Issue.			
AB	Azomethines (I, A = benzene, naphthalene, pyridine, quinoline, benzofuran, pyrimidine, pyrazole residue; B = benzene, naphthalene, quinoline residue) were prepared, isolated, and treated with Cu <sup>2+</sup> and Ni <sup>2+</sup> salts to give yellow to yellow green 1:1 azomethine pigments, useful for coloring plastics. Thus, a mixture of 2-HOC <sub>6</sub> H <sub>4</sub> CONHNH <sub>2</sub> [936-02-7] and 2,1-HOC <sub>10</sub> H <sub>6</sub> CHO [708-06-5] in HOAc were heated at 100° for 2 hr to give I (A = naphthalene, B = benzene residues) [54009-54-0] which was treated with Cu(OAc)·2·2H <sub>2</sub> O in Me Cellosolve to give 1:1 Cu complex [60265-88-5]. Ni and Cu 1:1 complexes of I were also prepared in a one-pot process.			
IT	60256-57-7P RL: IMF (Industrial manufacture); PREP (Preparation) (preparation of)			
RN	60256-57-7 CAPLUS			
CN	3-Quinolinecarboxylic acid, 1,2-dihydro-4-hydroxy-2-oxo-, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)			




L33 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1957:85704 CAPLUS  
 DN 51:85704  
 OREF 51:15512i,15513a-f  
 TI The Michael addition of 2-picoly-2-ketones  
 AU Beyer, Hans; Lassig, Wolfgang; Schudy, Gerhard  
 CS Univ. Greifswald, Germany  
 SO Chemische Berichte (1957), 90, 592-8  
 CODEN: CHBEAM; ISSN: 0009-2940  
 DT Journal  
 LA Unavailable  
 OS CASREACT 51:85704  
 AB The reaction of 2-pyridylacetone (I), 2-phenacylpyridine (II), and deoxypyridoin (III) with acrylonitrile (IV), MeCOCH:CH<sub>2</sub> (V), and PhCH:CHCO<sub>2</sub>Me (VI) has been studied. In general, IV, V, or VI in EtOH is added to I, II, or III in 10-20 cc. absolute EtOH containing a few platelets of KOH at below 60° and, after the initial reaction has subsided, the mixture is heated 5 min. on an H<sub>2</sub>O bath. The reaction mixture of 58 g. I and 24 g. IV is poured into 5 times its volume of H<sub>2</sub>O, 9 g. γ-(2-pyridyl)-2-γ-acetylpimelic acid dinitrile (VII) filtered off, the filtrate acidified, washed with Et<sub>2</sub>O, made alkaline, and extracted with Et<sub>2</sub>O or CHCl<sub>3</sub>, and  
 the residue of the dried extract distilled, giving 44.5% γ-(2-pyridyl)γ-acetylbutyric nitrile (VIII), b<sub>15</sub> 188-92°, m. 34°; it gives a blue-green color with FeCl<sub>3</sub> [phenylhydrazone (PH), needles, m. 180.5-1° (decomposition); picrate, shiny yellow leaflets, m. 124-5° (decomposition)]. Similarly, 15 g. I and 32 g. IV yield 82% VII,

needles, m. 111.5°; 9.4 g. VIII and 5.3 g. IV give 85% VII (PH, small rods, m. 161°; picrate, stout yellow columns, m. 134° (decomposition). Refluxing 1.9 g. VIII 0.5 hr. with 6 cc. concentrated H<sub>2</sub>SO<sub>4</sub>, diluting the mixture with 50 cc. H<sub>2</sub>O, neutralizing it with Na<sub>2</sub>CO<sub>3</sub>, and extracting with CHCl<sub>3</sub> give 83.5% γ-(2-pyridyl)γ-acetylbutyric acid (IX), clusters of crystals, m. 121°. Adding dropwise 5.3 g. IV in 10 cc. absolute EtOH to 23.3 g. II.HCl and 8 g. KOH in 30 cc. absolute EtOH, adding H<sub>2</sub>O, and extracting with Et<sub>2</sub>O yield 48% γ-Bz analog of VIII, rhombic plates, m. 75°, which, saponified, gives 89% Bz analog (X) of IX, rhombic leaflets, m. 134-5° (PH, m. 161°). Boiling 1.35 g. X with 2.8 g. KOH in 2 cc. H<sub>2</sub>O until colorless, neutralizing the mixture with 50 cc. N HCl, filtering off the BzOH, and extracting the residue of the evaporated filtrate with C<sub>6</sub>H<sub>6</sub> yield 79% γ-(2-pyridyl)butyric acid, m. 85°. Treating 4 g. III with 2.1 g. IV gives 51% γ-(2-pyridyl)γ-(2-pyridoyl)butyric acid nitrile, stout rhombs, m. 72°, which, saponified, yields 90% free acid, needles or leaflets, m. 108°. Treating 27 g. I with 18 cc. V gives 3-methyl-6-(2-pyridyl)-2-cyclohexen-1-one (XI), b<sub>12</sub> 154°; it gives a blue-green color with FeCl<sub>3</sub> [PH, needles, m. 151-2° (decomposition); picrate, rhombic yellow leaflets, m. 111-12° (decomposition)]. Heating 7.5 g. XI with 2 g. S 45 min. at 180°, extracting the mixture with Et<sub>2</sub>O, and distilling the residue of the extract yield 34% 3-methyl-6-(2-pyridyl)phenol, b<sub>2</sub> 155-60°, needles, m. 50°; it gives a blue-violet color with FeCl<sub>3</sub> [picrate, stout rhombic needles, m. 197° (decomposition)]. Treating 9.5 g. I with 14.5 g. VI yields 77% 3,5-diphenyl-6-(2-pyridyl)-2-cyclohexen-1-one (XII), shiny orange-yellow leaflets, m. 152°; green color with FeCl<sub>3</sub> [picrate, long yellow needles, m. 184° (decomposition); di-Br addition compound, prepared with Br-AcOH in AcOH, needles, m. 206-7°]. Heating 1.6 g. XII and 1 g. Se 2-3 hrs. at 200-50°, extracting the melt with EtOH, and concentrating the extract give 44% 3,5-diphenyl-6-(2-pyridyl)phenol, yellowish needles, m. 157.5°, violet color with FeCl<sub>3</sub>. Treating 4.6 g. II.HCl with 1.5 g. KOH and 1.5 g. V and extracting the mixture with Et<sub>2</sub>O yield 5-(2-pyridyl)-5-benzoyl-2-pentanone, needles, m. 166°. Similarly, 4 g. III and 3.5 g. V give 65% 5-(2-pyridyl)-5-(2-pyridoyl)-2-pentanone, rhombs, m. 151°; 11.7 g. II.HCl and 5 g. KOH in 50 cc. EtOH and 10.4 g. VI in 50 cc. EtOH yield 69% β-phenyl-γ-(2-pyridyl)-γ-benzoylbutyrophenone, needles, m. 188°; 3.2 g. III and 3.35 g. VI give 71% β-phenyl-γ-(2-pyridyl)-γ-(2-pyridoyl)butyrophenone, needles, m. 196-7°.

IT 102002-34-6P, Hydrazine, 1-(1-antipyrinylolethylidene)-2-(3,5-dibromosalicyloyl)-  
 RL: PREP (Preparation)  
 (preparation of)

RN 102002-34-6 CAPLUS

CN Salicylic acid, 3,5-dibromo-, (1-antipyrinylolethylidene)hydrazide (6CI)  
 (CA INDEX NAME)



L33 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1957:85703 CAPLUS

DN 51:85703

OREF 51:15512g-i

TI Synthesis of tuberculostatic compounds. V. Synthesis of some new hydrazones of salicylic acid hydrazide and 3,5-dibromosalicylic acid hydrazide

AU Klosa, Josef

CS ASAL Sci. Lab., Berlin

SO Arch. Pharm. (1955), 288, 49-52

DT Journal


LA Unavailable

AB cf. C.A. 51, 8086b, 14690f. The following new hydrazones of salicylic acid hydrazide were prepared (reactant and m.p. given): anisaldehyde, 218-19°; salicylaldehyde, 274-6°; cinnamaldehyde, 237°; vanillin, 215°; crotonaldehyde, 190-2°; furfural, 225-7°; antipyrinaldehyde, 214-16°; Me<sub>2</sub>CO, 231-2°; EtCOMe, 150°; cyclohexanone, 212-13° (decomposition); PhAc, 208-10° (decomposition); acetylantipyrine, 295°. The following new hydrazones of 3,5-dibromosalicylic acid hydrazide were prepared (reactant and m.p. given): BzH, 236°; anisaldehyde, 238°; salicylaldehyde, 200°; cinnamaldehyde, -; vanillin, 220°; furfural, 232°; antipyrinaldehyde, 242°; Me<sub>2</sub>CO, 204°; cyclohexanone, 182°; 4-acetylantipyrine, 228°. All compds. showed slight in vitro tuberculostatic activity.

IT 101868-30-8P, Hydrazine, 1-(antipyrinylmethylene)-2-(3,5-dibromosalicyloyl)- 102002-34-6P, Hydrazine, 1-(1-antipyrinylethylidene)-2-(3,5-dibromosalicyloyl)- 102017-61-8P, Hydrazine, 1-(antipyrinylmethylene)-2-salicyloyl- 102157-96-0P, Hydrazine, 1-(1-antipyrinylethylidene)-2-salicyloyl-  
 RL: PREP (Preparation)  
 (preparation of)


RN 101868-30-8 CAPLUS

CN Benzoic acid, 3,5-dibromo-2-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 102002-34-6 CAPLUS

CN Salicylic acid, 3,5-dibromo-, (1-antipyrinylylethylidene)hydrazide (6CI)  
(CA INDEX NAME)




RN 102017-61-8 CAPLUS

CN Benzoic acid, 2-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 102157-96-0 CAPLUS

CN Salicylic acid, (1-antipyrinyloxy)hydrazide (6CI) (CA INDEX NAME)





=> d his

(FILE 'HOME' ENTERED AT 11:46:54 ON 02 JUL 2007)

L1 FILE 'REGISTRY' ENTERED AT 11:47:00 ON 02 JUL 2007  
STRUCTURE UPLOADED  
L2 1270 S L1 SSS FULL  
SAV TEM BRD530482/A L2

FILE 'STNGUIDE' ENTERED AT 11:48:17 ON 02 JUL 2007

L3 FILE 'REGISTRY' ENTERED AT 11:56:39 ON 02 JUL 2007  
STRUCTURE UPLOADED  
L4 50 S L3 SAM SUB=L2  
L5 1125 S L3 SSS FULL SUB=L2

FILE 'STNGUIDE' ENTERED AT 11:57:29 ON 02 JUL 2007

FILE 'REGISTRY' ENTERED AT 11:57:53 ON 02 JUL 2007

FILE 'REGISTRY' ENTERED AT 11:58:02 ON 02 JUL 2007  
SAV TEM L5 BR2530482/A

L6 FILE 'CAPLUS' ENTERED AT 11:58:18 ON 02 JUL 2007  
102 S L5

FILE 'STNGUIDE' ENTERED AT 11:58:24 ON 02 JUL 2007

FILE 'REGISTRY' ENTERED AT 11:59:13 ON 02 JUL 2007

FILE 'STNGUIDE' ENTERED AT 11:59:46 ON 02 JUL 2007

L7 FILE 'REGISTRY' ENTERED AT 12:04:37 ON 02 JUL 2007  
STRUCTURE UPLOADED  
L8 43 S L7 SAM SUB=L5  
L9 739 S L7 SSS FULL SUB=L5  
SAV TEM L9 BR3530482/A

L10 FILE 'CAPLUS' ENTERED AT 12:05:48 ON 02 JUL 2007  
71 S L9

FILE 'STNGUIDE' ENTERED AT 12:05:58 ON 02 JUL 2007

FILE 'CAPLUS' ENTERED AT 13:06:57 ON 02 JUL 2007

FILE 'REGISTRY' ENTERED AT 13:06:59 ON 02 JUL 2007

=> d l1

L1 HAS NO ANSWERS

L1 STR

O

N

N


Hy-O

Structure attributes must be viewed using STN Express query preparation.

=> d 13

L3 HAS NO ANSWERS

L3 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 17

L7 HAS NO ANSWERS

L7 STR



CH<sup>1</sup>

2—Ak

3—Cy

G1 [@1], [@2], [@3]

Structure attributes must be viewed using STN Express query preparation.

=> s wo2003-jp12985/ap  
L12 1 WO2003-JP12985/AP

=> s l10 not l12  
L13 70 L10 NOT L12

L13 ANSWER 1 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:509808 CAPLUS <<LOGINID::20070702>>

DN 146:482060

TI Preparation of N'-[1-(5-oxo-4,5-dihydropyrazol-4-ylidene)ethyl]thiophene-2-carboxylic acid hydrazide derivatives as thrombopoietin receptor activator

IN Miyaji, Katsuaki; Shigeta, Yukihiro; Nakano, Satoshi; Ota, Hirofumi; Ishiwata, Norihisa

PA Nissan Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 232pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007052808	A1	20070510	WO 2006-JP322193	20061107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	JP 2005-322114	A	20051107		
OS	MARPAT 146:482060				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Hydrazides represented by the formula (I) [R1, R2 = H, CHO, each (un)substituted C1-10 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-10 alkoxy, or C1-10 alkylcarbonyl; R3 = (un)substituted C2-14 aryl; L1 = Q optionally fused with (un)substituted C2-14 aryl, C3-7 carbocyclyl, C2-9 heterocyclyl; A, B, D, E = (un)substituted CH or N; or A=B or D=E together represent O, S, or (un)substituted NH; L2 = a single bond, (un)substituted CH2 or NH, O, S; X = (un)substituted OH or SH; Y = O, S, (un)substituted NH], tautomers thereof, prodrugs thereof, pharmaceutically acceptable salts thereof or solvates thereof are prepared. A blood platelet-increasing drug containing the compound I is claimed. These compds. are effective in the prevention, treatment or improvement of a disease, e.g. thrombocytopenia, in which a thrombopoietin receptor activation action is effective. Thus, 1-(5-hydroxy-3-methyl-1-(3,4-dimethylphenyl)-1H-pyrazol-4-yl)ethanone was condensed with 5-hydrazinocarbonylthiophene-2-carboxylic acid isopropylamide in the presence of p-MeC6H4SO3H monohydrate in isopropanol under refluxing at 90° overnight to give 5-[[N'-[1-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid isopropylamide (II). II and 5-[[N'-[1-[1-(4-trifluoromethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid N-[(3-pyridyl)methyl]amide (III) promoted the growth of thrombopoietin-dependent human leukemia UT7/EPO-mp expressing human thrombopoietin receptor (c-mpl) with EC50 of 2.3 and 0.26 ng/mL, resp.

IT 935889-06-8P, 5-[[N'-[1-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid isopropylamide 935889-07-9P, 5-[[N'-[1-[1-(3,4-

Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid  
 N-[(4-pyridyl)methyl]amide 935889-08-0P, 1-[[5-[[N'-[1-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]pyrrolidine-3,4-diol 935889-09-1P, 1-[[5-[[N'-[1-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-yl]carbonyl]pyrrolidine 935889-10-4P, N',N'-Dimethyl-5-[[N'-[1-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic hydrazide 935889-11-5P, 1-[[5-[[N'-[1-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]-4-(pyrrolidin-1-yl)piperidine 935889-12-6P, 5-[[N'-[1-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid  
 N-[(2-pyridyl)methyl]amide 935889-13-7P, 5-[[N'-[1-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid  
 N-[(3-pyridyl)methyl]amide 935889-14-8P, 3-[[5-[[N'-[1-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]amino]propanoic acid 935889-15-9P, 5-[[N'-[1-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid methylamide 935889-16-0P, 5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid  
 isopropylamide 935889-17-1P, 5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid N-[(4-pyridyl)methyl]amide 935889-18-2P, 1-[[5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]pyrrolidine-3,4-diol 935889-19-3P, 5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid diethylamide 935889-20-6P, 1-[[5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]pyrrolidine 935889-21-7P, N',N'-Dimethyl-5-[[N'-[1-[1-(4-tert-butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic hydrazide 935889-22-8P, 1-[[5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]-4-(pyrrolidin-1-yl)piperidine 935889-23-9P, 1-[[5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]-3-dimethylaminopyrrolidine 935889-24-0P, 5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid  
 N-[(2-pyridyl)methyl]amide 935889-25-1P, 5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid  
 N-[(3-pyridyl)methyl]amide 935889-26-2P, 4-[[5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]amino]morpholine 935889-27-3P, 1-[[5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]-3,4-dimethoxypyrrolidine 935889-28-4P, 2-[[5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]amino]acetic acid 935889-29-5P, 3-[[5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]amino]propanoic acid 935889-30-8P, 5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid methylamide 935889-31-9P, 5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-


dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid N-(2-methoxyethyl)amide 935889-32-0P, 5-[[N'-[1-[1-(4-tert-Butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid propylamide 935889-33-1P, 5-[[N'-[1-[1-(4-Trifluoromethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid isopropylamide 935889-34-2P, 5-[[N'-[1-[1-(4-Trifluoromethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid N-[(4-pyridyl)methyl]amide 935889-35-3P, 1-[[5-[[N'-[1-[1-(4-Trifluoromethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]pyrrolidine-3,4-diol 935889-36-4P, 5-[[N'-[1-[1-(4-Trifluoromethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid diethylamide 935889-37-5P, 1-[[5-[[N'-[1-[1-(4-Trifluoromethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]pyrrolidine 935889-38-6P, N',N'-Dimethyl-5-[[N'-[1-[1-(4-trifluoromethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic hydrazide 935889-39-7P, 1-[[5-[[N'-[1-[1-(4-Trifluoromethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]-4-(pyrrolidin-1-yl)piperidine 935889-40-0P, 1-[[5-[[N'-[1-[1-(4-Trifluoromethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]-3-dimethylaminopyrrolidine 935889-41-1P, 5-[[N'-[1-[1-(4-Trifluoromethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid N-[(2-pyridyl)methyl]amide 935889-42-2P, 5-[[N'-[1-[1-(3,4-Dichlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid isopropylamide 935889-43-3P, 5-[[N'-[1-[1-(3,4-Dichlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid N-[(4-pyridyl)methyl]amide 935889-44-4P, 1-[[5-[[N'-[1-[1-(3,4-Dichlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]pyrrolidine-3,4-diol 935889-45-5P, 5-[[N'-[1-[1-(3,4-Dichlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid dimethylamide 935889-46-6P, 1-[[5-[[N'-[1-[1-(3,4-Dichlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]-4-(pyrrolidin-1-yl)piperidine 935889-47-7P, 5-[[N'-[1-[1-(3,4-Dichlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid N-[(2-pyridyl)methyl]amide 935889-48-8P, 5-[[N'-[1-[1-(3,4-Dichlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophene-2-carboxylic acid N-[(3-pyridyl)methyl]amide 935889-49-9P, 1-[[5-[[N'-[1-[1-(3,4-Dichlorophenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]ethyl]hydrazino]carbonyl]thiophen-2-yl]carbonyl]-3,4-dimethoxypyrrolidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N'-[1-(5-oxo-4,5-dihydropyrazol-4-ylidene)ethyl]thiophene-2-carboxylic acid hydrazide derivs. as thrombopoietin receptor activators and blood platelet-increasing agents)


RN 935889-06-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[(1-methylethyl)amino]carbonyl]-, 2-[1-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-07-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[4-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-08-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[4-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-09-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[4-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-10-4 CAPLUS

CN 2,5-Thiophenedicarboxylic acid, 2-(2,2-dimethylhydrazide)  
5-[2-[1-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide] (CA INDEX NAME)




RN 935889-11-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]-  
, 2-[1-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)



RN 935889-12-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[2-(pyridinylmethyl)amino]carbonyl]-,  
2-[1-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)



RN 935889-13-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[3-(pyridinylmethyl)amino]carbonyl]-,  
2-[1-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)






RN 935889-14-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[(2-carboxyethyl)amino]carbonyl]-, 2-[2-[1-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide] (CA INDEX NAME)




RN 935889-15-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(methalamino)carbonyl]-, 2-[1-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-16-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[(1-methylethyl)amino]carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-17-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[(4-pyridinylmethyl)amino]carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-18-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(3,4-dihydroxy-1-pyrrolidinyl)carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-19-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(diethylamino)carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-20-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1-pyrrolidinylcarbonyl)-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-21-7 CAPLUS

CN 2,5-Thiophenedicarboxylic acid, 2-(2,2-dimethylhydrazide)  
5-[2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide] (CA INDEX NAME)




RN 935889-22-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)



RN 935889-23-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)



RN 935889-24-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[2-(pyridinylmethyl)amino]carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)

2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-25-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[3-pyridinylmethyl)amino]carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-26-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(4-morpholinylamino)carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-27-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(3,4-dimethoxy-1-pyrrolidinyl)carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-28-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[(carboxymethyl)amino]carbonyl]-, 2-[2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide] (CA INDEX NAME)




RN 935889-29-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[(2-carboxyethyl)amino]carbonyl]-, 2-[2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide] (CA INDEX NAME)




RN 935889-30-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(methylamino)carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-31-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[(2-methoxyethyl)amino]carbonyl]-, 2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-32-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(propylamino)carbonyl]-,  
2-[1-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-  
pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-33-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[(1-methylethyl)amino]carbonyl]-,  
2-[1-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-  
4-ylidene]ethyl]hydrazide (CA INDEX NAME)



RN 935889-34-2 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[[(4-pyridinylmethyl)amino]carbonyl]-,  
2-[1-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-  
4-ylidene]ethyl]hydrazide (CA INDEX NAME)



RN 935889-35-3 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[(3,4-dihydroxy-1-pyrrolidinyl)carbonyl]-,

2-[1-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-36-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(diethylamino)carbonyl]-, 2-[1-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-37-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1-pyrrolidinylcarbonyl)-, 2-[1-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-38-6 CAPLUS

CN 2,5-Thiophenedicarboxylic acid, 2-[2-[1-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]ethyl]hydrazide] 5-(2,2-dimethylhydrazide) (CA INDEX NAME)




RN 935889-39-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]-  
, 2-[1-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-  
pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-40-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-  
, 2-[1-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-  
pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)



RN 935889-41-1 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[[(2-pyridinylmethyl)amino]carbonyl]-,  
2-[1-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-  
4-ylidene]ethyl]hydrazide. (CA INDEX NAME)



RN 935889-42-2 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[[[(1-methylethyl)amino]carbonyl]-,  
2-[1-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-  
ylidene]ethyl]hydrazide (CA INDEX NAME)






RN 935889-43-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[4-pyridinylmethyl)amino]carbonyl]-, 2-[1-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-44-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(3,4-dihydroxy-1-pyrrolidinyl)carbonyl]-, 2-[1-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-45-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(dimethylamino)carbonyl]-, 2-[1-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-46-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]-, 2-[1-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-47-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[(2-pyridinylmethyl)amino]carbonyl]-, 2-[1-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-48-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[[(3-pyridinylmethyl)amino]carbonyl]-, 2-[1-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)




RN 935889-49-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[(3,4-dimethoxy-1-pyrrolidinyl)carbonyl]-, 2-[1-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]ethyl]hydrazide (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2007:347171 CAPLUS <<LOGINID::20070702>>  
DN 146:512947  
TI Neutral dioxovanadium(V) complexes of biomimetic hydrazones ONO donor ligands of bioinorganic and medicinal relevance: Synthesis via air oxidation of bis(acetylacetonato)oxovanadium(IV), characterization, biological activity and 3D molecular modeling  
AU Maurya, R. C.; Rajput, S.  
CS Coordination Chemistry Laboratory, Department of P.G. Studies and Research in Chemistry, R.D. University, Jabalpur, 482 001, India  
SO Journal of Molecular Structure (2007), 833(1-3), 133-144  
CODEN: JMOSB4; ISSN: 0022-2860  
PB Elsevier B.V.  
DT Journal  
LA English  
AB The interaction of [VO(acac)<sub>2</sub>] with biomimetic hydrazone ONO donor ligands HL in 1:1 mol ratio [where, HL = N-(4'-benzoylidene-3'-methyl-1'-phenyl-2'-pyrazolin-5'-one)-isonicotinic acid hydrazide (bmphp-inH, I), N-(4'-butyrylidene-3'-methyl-1'-phenyl-2'-pyrazolin-5'-one)-isonicotinic acid hydrazide (bumphp-inH, II), N-(4'-acetylidene-3'-methyl-1'-phenyl-2'-pyrazolin-5'-one)-isonicotinic acid hydrazide (amphp-inH, III), N-(3'-methyl-1'-phenyl-4'-propionylidene-2'-pyrazolin-5'-one)-isonicotinic acid hydrazide (mphpp-inH, IV) and N-(4'-iso-butyrylidene-3'-methyl-1'-phenyl-2'-pyrazolin-5'-one)-isonicotinic acid hydrazide (iso-bumphp-inH, V)] in a mixed solvent (EtOH-MeOH, 1:10) via aerial oxidation for 2-3 days yield dioxovanadium(V) complexes [VO<sub>2</sub>(L)(H<sub>2</sub>O)]·H<sub>2</sub>O. The compds. so obtained were characterized from elemental analyses, TG, V determination, IR, electronic, 51V NMR, 1H NMR and mass spectral studies. The 3-dimensional mol. modeling and anal. for bond lengths and bond angles also were carried out for one of the representative compds., [VO<sub>2</sub>(amphp-in)(H<sub>2</sub>O)] (3).  
IT 925423-36-5P  
RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reactant for preparation of vanadium oxo pyrazolinone isonicotinic hydrazone complex)  
RN 925423-36-5 CAPLUS  
CN 4-Pyridinecarboxylic acid, 2-[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)butylidene]hydrazide (CA INDEX NAME)




IT 329247-15-6P 925423-37-6P 925423-38-7P  
925423-39-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reactant for preparation of vanadium oxo pyrazolinone isonicotinic hydrazone complex)


RN 329247-15-6 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (CA INDEX NAME)




RN 925423-37-6 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)ethylidene]hydrazide (CA INDEX NAME)




RN 925423-38-7 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)propylidene]hydrazide (CA INDEX NAME)



RN 925423-39-8 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)-2-methylpropylidene]hydrazide (CA INDEX NAME)



RE.CNT 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2007:61833 CAPLUS <<LOGINID::20070702>>  
DN 146:156276  
TI Cellular cholesterol absorption modifiers  
IN Gardiner, Elisabeth M.; Duron, Wergio G.; Massari, Mark E.; Severance, Daniel L.; Semple, Joseph E.; Smith, Nicholas D.  
PA Kalypsys, Inc., USA  
SO PCT Int. Appl., 76pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007008529	A2	20070118	WO 2006-US26197	20060706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-697687P	P	20050708		
	US 2005-727652P	P	20051017		
	US 2006-781972P	P	20060313		
OS	MARPAT 146:156276				
AB	The present invention relates to compds. and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of cholesterol-related diseases, such as atherosclerosis (Markush structures given). Fifty-two novel aromatic diaza derivs. that prevent cholesterol absorption by inhibition of NPC1L1 were prepared and their antihypercholesterolemic activity is shown.				
IT	330590-00-6P 339242-35-2P 339242-87-4P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				

(cellular cholesterol absorption modifiers)

RN 330590-00-6 CAPLUS

CN Benzoic acid, 4-hydroxy-, 2-[[1-(3-chlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 339242-35-2 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (CA INDEX NAME)



RN 339242-87-4 CAPLUS  
 CN Benzoic acid, 2-[[1-(3-chlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (CA INDEX NAME)




L13 ANSWER 4 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1098053 CAPLUS <<LOGINID::20070702>>  
 DN 145:438636  
 TI Novel compounds for treatment of cancer and disorders associated with angiogenesis function and their preparation and pharmaceutical compositions  
 IN Neamati, Nouri  
 PA USA



SO U.S. Pat. Appl. Publ., 74pp., Cont.-in-part of U.S. Ser. No. 27,465.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006235034	A1	20061019	US 2005-265593	20051101
	US 2006142294	A1	20060629	US 2004-27465	20041229
PRAI	US 2004-624253P	P	20041101		
GI	US 2004-27465	A2	20041229		




AB Novel compds. for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compds., pharmaceutical compns. and packaged products containing the compds., a method of using these mols. to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression. Example compound I was prepared by condensation of 7-fluoro-4-hydrazinopyrrolo[1,2-a]quinoxaline with 2-pyrazinecarboxylic acid. All the invention compds. were evaluated for their antitumor and antiangiogenesis activity. Compound I showed good activity against various genes.

IT 331238-74-5 908254-85-3  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of aryl hydrazides for treatment of cancer and disorders associated with angiogenesis function)


RN 331238-74-5 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)



RN 908254-85-3 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)methyl]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 5 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:904530 CAPLUS <<LOGINID::20070702>>

DN 145:464735

TI Study on DNA-binding properties and cytotoxicity in L1210 of La(III) complex with PMBP-isonicotinoyl hydrazone

AU Yang, Zheng-Yih; Wang, Bao-Dui; Li, Yan-Hua

CS School of Chemistry and Chemical Engineering and State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, 730000, Peop. Rep. China

SO Journal of Organometallic Chemistry (2006), 691(20), 4159-4166

CODEN: JORCAI; ISSN: 0022-328X

PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 145:464735

AB La(III) complex with 1-phenyl-3-methyl-5-hydroxy-4-pyrazolyl Ph ketone (PMBP)-isonicotinoyl hydrazone (La-complex) was synthesized. The crystal of the La-complex was determined by x-ray diffraction analyses, the crystal of the complex is rhomb, space group R 3 with Z = 6, the coordination polyhedron of the complex is a tricapped trip prism configuration with the


nine-coordinate atoms, and the La-complex mol. looks like a helix structure according to its space fill picture. Besides, the La-complex possesses cytotoxic activities, and inhibitory rate for Leukemia cells (L1210) is 87.1%. The interaction of the La-complex with DNA was studied by absorption spectrum, fluorescence, CD spectrum and viscosity measurements. The DNA-binding constant for the La-complex is  $(4.30 \pm 0.14) \times 10^6 \text{ M}^{-1}$ .

IT 221524-99-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(complexation with lanthanum)

RN 221524-99-8 CAPLUS

CN 4-Pyridinecarboxylic acid, [(2,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:885044 CAPLUS <<LOGINID::20070702>>

DN 145:285109

TI Novel compounds for treatment of cancer and disorders associated with angiogenesis function

IN Neamati, Nouri; Garofalo, Antonio

PA University of Southern California, USA

SO PCT Int. Appl., 127pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006091246	A1	20060831	WO 2005-US39687	20051101
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,</p>				

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 US 2006142294 A1 20060629 US 2004-27465 20041229  
 PRAI US 2004-624253P P 20041101  
 US 2004-27465 A 20041229  
 OS MARPAT 145:285109  
 GI



I



II

AB Disclosed are novel compds. I [X = CH or N; Z = O or S; R and R1 independently = alkyl, halo, acetyl, O-alkyl, or N-alkyl; Y = alkyl, heteroaryl, sugar, etc.] for treatment of cancer and disorders associated with angiogenesis function. Methods for preparing a subset of invention compds. are presented. Thus, e.g., II was prepd. by reaction of 4-hydrazino-7,8-dimethylpyrrolo[1,2-a]quinoxaline with 2-pyrazinecarboxylic acid. Addnl., pharmacophore anal. of a 10,000 compound database of reported and patented integrase inhibitors led to acquiring numerous analogs of salicylhydrazides from com. sources and these compds. were then subjected to cytotoxicity assays. Also disclosed are a method of preparing the compds., pharmaceutical compns. and packaged products containing

the compds., a method of using these mols. to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.


IT 331238-74-5 908254-85-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel compound for treatment of cancer and disorders associated with angiogenesis function)


RN 331238-74-5 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)



RN 908254-85-3 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)methyl]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:539400 CAPLUS <<LOGINID::20070702>>

DN 146:265035

TI Synthesis and characterization of some vanadium(IV) and vanadium(V) complexes

AU Maurya, R. C.; Rajput, S.

CS Coordination Chemistry Laboratory, Department of Post Graduate Studies and Research in Chemistry, R.D. University, Jabalpur, 482 001, India

SO Progress in Crystal Growth and Characterization of Materials (2006), 52(1-2), 142-149

CODEN: PCGMED; ISSN: 0960-8974

PB Elsevier Ltd.

DT Journal

LA English

AB The synthesis and characterization of two series of V compds.: (a) oxovanadium(IV) complexes [VO(L1)(L2)(H2O)] L1H = 4-benzoyl-3-methyl-1-phenyl-2-pyrazoline-5-one (bmpph), L2H = acetoacetanilide (aaH), o-acetoacetotoluidide (o-aatdH), o-acetoacetanilide (o-aansH),

methylacetoacetate (macacH), ethylacetoacetate (eacacH) or dibenzoylmethane (dbmH), and (b) dioxovanadium(V) complexes with Schiff bases (aroylhydrazones)  $[VO_2(L)(H_2O)] \cdot H_2O$  LH = Schiff base derived from isonicotinic acid hydrazide (inH) and bumpph, 4-butyryl-3-methyl-1-phenyl-2-pyrazolin-5-one (bumpph), 4-acetyl-3-methyl-1-phenyl-2-pyrazolin-5-one (ampph), 3-methyl-1-phenyl-4-propionyl-2-pyrazolin-5-one (pmpph) or 4-iso-butyryl-3-methyl-1-phenyl-2-pyrazolin-5-one (iso-bumpph) is presented. The 3-dimensional-mol. modeling and anal. for bond lengths and bond angles also were carried out for one representative compound of each series.

IT 329247-15-6P 925423-36-5P 925423-37-6P


925423-38-7P 925423-39-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and complexation with vanadium(V))


RN 329247-15-6 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (CA INDEX NAME)




RN 925423-36-5 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)butylidene]hydrazide (CA INDEX NAME)




RN 925423-37-6 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)ethylidene]hydrazide (CA INDEX NAME)




RN 925423-38-7 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)propylidene]hydrazide (CA INDEX NAME)




RN 925423-39-8 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)-2-methylpropylidene]hydrazide (CA INDEX NAME)




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:55427 CAPLUS <<LOGINID::20070702>>  
DN 145:368692  
TI Studies on synthesis and antioxidative activity of transitional complexes  
of PMBP-benzoyl hydrazone  
AU Yang, Zhengyin; Zheng, Jinfu; Yang, Chunli  
CS College of Chemistry and Chemical Engineering, Lanzhou University,  
Lanzhou, 730000, Peop. Rep. China  
SO Lanzhou Daxue Xuebao, Ziran Kexueban (2004), 40(6), 51-54  
CODEN: LCTHAF; ISSN: 0455-2059  
PB Lanzhou Daxue  
DT Journal  
LA Chinese  
OS CASREACT 145:368692  
AB 1-Phenyl-3-methyl-5-hydroxy-4-pyrazolyl Ph ketone benzoyl hydrazone  
(H2PBB) was prepared by condensation of 1-phenyl-3-methyl-4-benzoyl-5-  
pyrazolone with benzoyl hydrazine. Six complexes of transition metals  
with H2PBB were synthesized and characterized by elemental analyses, IR,  
UV, <sup>1</sup>H NMR spectra and thermal analyses, resp. The results showed that  
the transition metal complexes of H2PBB had antioxidative activity to  
certain extent.  
IT 183113-24-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of transitional complexes of PMBP-benzoyl hydrazone)  
RN 183113-24-8 CAPLUS  
CN Benzoic acid, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-  
yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)






L13 ANSWER 9 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:15425 CAPLUS <<LOGINID::20070702>>  
 DN 144:245927  
 TI Synthesis and structural characterization of three hydrogen-bonding  
 connected supramolecular complexes of nickel, zinc and copper with  
 1,3-diphenyl-4-(salicylhydrazide acetyl)pyrazolone-5 and 2,2'-bipyridine  
 AU Hu, Xin; Zhang, Li; Liu, Lang; Liu, Guangfei; Jia, Dianzeng; Xu, Guancheng  
 CS Institute of Applied Chemistry, Xinjiang University, Urumqi, Xinjiang  
 Province, 830046, Peop. Rep. China  
 SO Inorganica Chimica Acta (2006), 359(2), 633-641  
 CODEN: ICHAA3; ISSN: 0020-1693  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 OS CASREACT 144:245927  
 GI




AB A new set of supramol. complexes, [Ni(DPAP-SHZ)(2,2'-bipy)CH<sub>3</sub>OH] (1),  
 [Zn(DPAP-SHZ)(2,2'-bipy)CH<sub>3</sub>OH] (2) and [Cu(DPAP-SHZ)(2,2'-  
 bipy)]·2CH<sub>2</sub>Cl<sub>2</sub> (3) (H<sub>2</sub>DPAP-SHZ = 1,3-diphenyl-4-(salicylhydrazide  
 acetyl)-pyrazolone-5 (I), 2,2'-bipy = 2,2'-bipyridine) were synthesized  
 and characterized by elemental anal., TG-DTA, IR spectroscopy and x-ray  
 crystallog. The x-ray diffraction analyses of the complexes show that the  
 Ni(II) ion and Zn(II) ion centers are six-coordinated while the Cu(II) ion  
 center is five-coordinated. The three supramol. complexes contain the  
 same ligands, DPAP-SHZ and 2,2'-bipy. However, their hydrogen bonds are  
 significantly different, and this variation apparently is responsible for  
 the dissimilar structures of the three supramol. complexes.  
 IT 876610-67-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of nickel, zinc and copper diphenyl(salicylhydrazide  
 acetyl)pyrazolone bipyridine complexes)  
 RN 876610-67-2 CAPLUS  
 CN Benzoic acid, 2-hydroxy-, [1-(4,5-dihydro-5-oxo-1,3-diphenyl-1H-pyrazol-4-  
 yl)ethylidene]hydrazide (9CI) (CA INDEX NAME)




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:1124572 CAPLUS <<LOGINID::20070702>>  
DN 144:245848  
TI Complexes of iron(III) with 1,2-dihydro-1,5-dimethyl-2-phenyl-4-benzoylhydrazonomethyl-3H-pyrazol-3-one  
AU Radhakrishnan, P. K.; Raju, K. C.  
CS School of Chemical Sciences, Mahatma Gandhi University, Kottayam, India  
SO Indian Journal of Chemistry, Section A: Inorganic, Bio-inorganic, Physical, Theoretical & Analytical Chemistry (2005), 44A(9), 1812-1816  
CODEN: ICACEC; ISSN: 0376-4710  
PB National Institute of Science Communication and Information Resources  
DT Journal  
LA English  
OS CASREACT 144:245848  
AB Fe(III) complexes of the Schiff base, 1,2-dihydro-1,5-dimethyl-2-phenyl-4-benzoylhydrazonomethyl-3H-pyrazol-3-one, [Fe(DPFBP)2X]X2 (X = ClO4, or NO3) and [Fe(DPFBP)2X2]X (X = SCN, Cl or Br), were synthesized and characterized by elemental analyses, elec. conductance in nonaq. solvents, IR, and electronic spectra as well as magnetic susceptibility measurements. In these complexes, DPFBP acts as a neutral bidentate ligand coordinating through the azomethine N and the carbonyl O of the pyrazolone ring. The molar conductance of the complexes in DMF, MeOH and nitrobenzene are in the range suggested for 1:2 electrolytes for perchlorate and nitrate complexes while the thiocyanate, chloride and bromide complexes behave as 1:1 electrolytes. The electronic spectra of the complexes exhibit a band in the region 19,230-20,080 cm<sup>-1</sup> due to 6A<sub>1g</sub> → 4T<sub>1g</sub>, consistent with octahedral Fe(III) complexes. The molar magnetic moment of the complexes varies in the range 5.61-6.05 μB, indicative of octahedral geometry.  
IT 76644-54-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and complexation with iron(III) salts)  
RN 76644-54-7 CAPLUS  
CN Benzoic acid, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:1069402 CAPLUS <<LOGINID::20070702>>  
DN 144:331321  
TI Crystal structure of a novel compound. 1-Phenyl-3-methyl-4-[2-(salicylhydrazido)propylidene]-5-pyrazolone  
AU Chai, Hui; Liu, Guang-Fei; Liu, Lang; Jia, Dian-Zeng  
CS Institute of Applied Chemistry, Xinjiang University, Urumqi, Xinjiang, 830046, Peop. Rep. China  
SO Jiegou Huaxue (2005), 24(9), 1091-1095  
CODEN: JHUADF; ISSN: 0254-5861  
PB Jiegou Huaxue Bianji Weiyuanhui  
DT Journal  
LA English  
OS CASREACT 144:331321  
AB A novel compound 1-phenyl-3-methyl-4-[2-(salicylhydrazido)propylidene]-5-pyrazolone was synthesized and characterized by elemental anal., IR, <sup>1</sup>H NMR and single-crystal x-ray diffraction. The x-ray diffraction reveals that the compound is of orthorhombic, space group Pbca with a = 16.132(5), b = 10.113(3), c = 23.143(7) Å, V = 3776(2) Å<sup>3</sup>, Z = 8, C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>, Mr = 364.40, D<sub>c</sub> = 1.282 g/cm<sup>3</sup>, F(000) = 1536, μ(MoKα) = 0.089 mm<sup>-1</sup>, S = 0.992, R = 0.0578 and wR = 0.1362 for 1871 observed reflections with I > 2σ(I). In the crystal, the compound possesses two C = O bonds and exists in the NH-form' other than NH-form.  
IT 331668-46-3P  
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and crystal structure of phenyl-methyl(salicylhydrazido)propylidene-pyrazolone)  
RN 331668-46-3 CAPLUS  
CN Benzoic acid, 2-hydroxy-, 2-[1-(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)propyl]hydrazide (9CI) (CA INDEX NAME)




RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:811974 CAPLUS <<LOGINID::20070702>>  
DN 144:99824  
TI Synthesis and crystal structure of mixed-ligand Cu(II) complex of  
N-[(1-phenyl-3-methyl-5-pyrazolon-4-yl)benzylidene]-N'-(p-  
nitrobenzoyl)hydrazine and pyridine  
AU Zhang, Li; Liu, Lang; Liu, Guang-Fei; Xu, Guan-Cheng; Jia, Dian-Zeng;  
Lang, Jian-Ping  
CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop.  
Rep. China  
SO Journal of Chemical Crystallography (2005), 35(8), 583-588  
CODEN: JCCYEV; ISSN: 1074-1542  
PB Springer  
DT Journal  
LA English  
OS CASREACT 144:99824  
GI



AB A new mixed-ligand copper(II) complex, [Cu(PMBP-PNH)Py], (PMBP-PNH =  
N-[(1-phenyl-3-methyl-5-pyrazolon-4-yl)benzylidene]-N'-(p-  
nitrobenzoyl)hydrazine (I) ; Py = pyridine), was synthesized by  
solvothermal method and characterized by elemental anal., IR spectrum,  
thermal anal. and single crystal x-ray diffraction (monoclinic, space  
group Cc with a 6.0422(8), b 22.796(3), c 18.353(3) Å, β  
93.199(3)°, Mr = 582.08, Z = 4). The copper(II) ion in the title  
complex is in a slightly distorted square-planar arrangement of the ONO  
donor atoms of primary ligand PMBP-PNH and one N-donor atom in the  
secondary ligand pyridine.  
IT 777063-77-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reactant for solvothermal preparation of copper(II)  
(phenyl(methyl)pyrazolonyl)benzylidene)(nitrobenzoyl)hydrazine  
pyridine complex)  
RN 777063-77-1 CAPLUS  
CN Benzoic acid, 4-nitro-, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-  
yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:610650 CAPLUS <<LOGINID::20070702>>

DN 143:318545

TI Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines

AU Plasencia, Carmen; Dayam, Raveendra; Wang, Qingcai; Pinski, Jacek; Burke, Terrence R., Jr.; Quinn, David I.; Neamati, Nouri

CS Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California, CA, USA

SO Molecular Cancer Therapeutics (2005), 4(7), 1105-1113

CODEN: MCTOCF; ISSN: 1535-7163

PB American Association for Cancer Research

DT Journal

LA English


AB We discovered a series of salicylhydrazide class of compds. with remarkable anticancer activity against a panel of hormone receptor-pos. and -neg. cell lines. In the present study, we evaluated the in vitro activity of SC21 and SC23 against a range of human tumor cell types and the in vivo efficacy of compound SC21 in a PC3 human prostate cancer xenograft model in mice. We also determined the effects of SC21 on cell cycle regulation and apoptosis. Our in vitro results show that salicylhydrazides are highly potent compds. effective in both hormone receptor-pos. and -neg. cancer cells. SC21 induced apoptosis and blocked the cell cycle in G0/G1 or S phase, depending on the cell lines used and irresp. of p53, p21, pRb, and p16 status. SC21 effectively reduced the tumor growth in mice without apparent toxicity. Although the mechanism of action of SC21 is not completely elucidated, the effect on cell cycle, the induction of apoptosis and the activity against a panel of tumor cell lines of different origins prompted us to carry out an in-depth preclin. evaluation of SC21.

IT 331238-74-5 382173-67-3


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (discovery and preclin. evaluation of salicylhydrazides in hormone-dependent and -independent cancer cell lines)

RN 331238-74-5 CAPLUS

CN Benzoic acid, 2-hydroxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)




RN 382173-67-3 CAPLUS  
 CN Benzoic acid, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)methyl]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 14 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:421924 CAPLUS <<LOGINID::20070702>>  
 DN 143:431451  
 TI Solid-state and liquid-state syntheses and characterization of Cu(II) complexes of pyrazolone derivatives  
 AU Feng, Ting; Liu, Lang; Zhang, Li; Jia, Dian-Zeng  
 CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop. Rep. China  
 SO Yingyong Huaxue (2005), 22(4), 372-376  
 CODEN: YIHUED; ISSN: 1000-0518  
 PB Kexue Chubanshe  
 DT Journal  
 LA Chinese  
 OS CASREACT 143:431451  
 AB Several Cu(II) complexes were synthesized by solid-state reaction and liquid-state reaction of pyrazolone derivs. with cupric acetate, resp., and characterized by elemental anal., IR, TG-DTA and XRD techniques. The results show that the solid-state reaction and liquid-state reaction lead to different products. The mol. formula of the liquid-state reaction products are M<sub>2</sub>L<sub>2</sub>·nH<sub>2</sub>O (n = 0, 1) and those of the solid-state reaction products are M(H<sub>2</sub>L)·2OAc·nH<sub>2</sub>O (n = 1, 2).  
 IT 329247-15-6 387829-06-3 777063-77-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (solid-state and liquid-state syntheses and characterization of Cu(II) complexes of pyrazolone derivs.)  
 RN 329247-15-6 CAPLUS  
 CN 4-Pyridinecarboxylic acid, 2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-

pyrazol-4-yl)phenylmethylene]hydrazide (CA INDEX NAME)




RN 387829-06-3 CAPLUS

CN Benzoic acid, 2-hydroxy-, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



RN 777063-77-1 CAPLUS

CN Benzoic acid, 4-nitro-, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 15 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:369234 CAPLUS <<LOGINID::20070702>>

DN 142:404249

TI Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation

IN Han, Hyunsil; Lin, Gang; Nathan, Carl F.

PA Cornell Research Foundation, Inc., USA

SO PCT Int. Appl., 77 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037213	A2	20050428	WO 2004-US33914	20041014
	WO 2005037213	A3	20060713		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2007021448	A1	20070125	US 2006-575683	20060831
PRAI	US 2003-510843P	P	20031014		
	WO 2004-US33914	W	20041014		
OS	MARPAT 142:404249				
GI					







I




II



III



IV



V

AB The present invention relates to a method of treating an inflammatory disorder in a subject with an effective amount of compound having the general formula I-V as described in the present application, under conditions effective to treat the inflammatory disorder. The present invention also relates to a method of inhibiting respiratory burst in neutrophils without inhibiting degranulation in or bacterial killing by the neutrophils by contacting neutrophils with the compds. described above. A combinatorial library of 15,000 compds. was screened for specific inhibitors of TNF- and PMA-triggered H2O2 release by primary human neutrophils. A small number of compds. were identified as capable of inhibiting TNF-triggered respiratory burst, as measured by H2O2 release, without inhibiting PMA-triggered respiratory burst.


IT 339094-91-6 339096-49-0 339242-13-6  
339242-15-8 339242-87-4 342584-72-9  
382598-68-7

RL: BSU (Biological study, unclassified); CST (Combinatorial study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); USES (Uses)  
(treatment of inflammatory disorder or inhibition of respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation)


RN 339094-91-6 CAPLUS

CN Benzoic acid, 3-bromo-, 2-[[1,5-dihydro-3-methyl-1-(4-methylphenyl)-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 339096-49-0 CAPLUS  
CN Benzoic acid, 3-nitro-, 2-[[1,5-dihydro-3-methyl-1-(3-methylphenyl)-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (9CI) (CA INDEX NAME)




RN 339242-13-6 CAPLUS

CN Benzoic acid, 2-nitro-, 2-[[1-(3-chlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (9CI) (CA INDEX NAME)




RN 339242-15-8 CAPLUS

CN Benzoic acid, 3-nitro-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)methyl]hydrazide (9CI) (CA INDEX NAME)



RN 339242-87-4 CAPLUS


CN Benzoic acid, 2-[[1-(3-chlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (CA INDEX NAME)




RN 342584-72-9 CAPLUS

CN Benzoic acid, 2-nitro-, 2-[[1,5-dihydro-3-methyl-1-(4-methylphenyl)-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A



RN 382598-68-7 CAPLUS  
CN Benzoic acid, 3-nitro-, 2-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]methyl]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 16 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:320885 CAPLUS <<LOGINID::20070702>>  
 DN 143:317820  
 TI Thermal kinetic TG-analysis of the mixed-ligand copper(II) and nickel(II) complexes of N-(1-phenyl-3-methyl-4-benzylidene-5-pyrazolone) p-nitrobenzoylhydrazide and pyridine  
 AU Xu, Guan-Cheng; Zhang, Li; Liu, Lang; Liu, Guang-Fei; Jia, Dian-Zeng  
 CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop. Rep. China  
 SO Thermochimica Acta (2005), 429(1), 31-42  
 CODEN: THACAS; ISSN: 0040-6031  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 OS CASREACT 143:317820  
 AB Thermal behaviors of three mixed-ligand complexes, [Ni(PMBP-PNH)(Py)<sub>3</sub>], [Ni(PMBP-PNH)Py] and [Cu(PMBP-PNH)Py] (PMBP-PNH = N-(1-phenyl-3-methyl-4-benzylidene-5-pyrazolone) p-nitrobenzoylhydrazide; Py = pyridine), were studied by TG and DTG in dynamic air atmospheric The complexes show the loss of pyridine mol. which is followed by the decomposition of the PMBP-PNH anion and give resp. metal oxides as residues. Meanwhile, the Ozawa-Flynn-Wall

model-free analyses and multivariate nonlinear regression were applied to perform single and overall steps optimization. Kinetic parameters were given and the most probable mechanism functions were suggested.


IT 777063-77-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant for preparation of copper(II) and nickel(II) complexes with N-(benzylidene-pyrazolone)p-nitrobenzoylhydrazide and pyridine)

RN 777063-77-1 CAPLUS

CN Benzoic acid, 4-nitro-, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 17 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:38342 CAPLUS <<LOGINID::20070702>>

DN 143:108428

TI Synthesis and characterization of lanthanide(III) complexes of 1-phenyl-3-methyl-5-hydroxy-4-pyrazolyl propionyl-2'-picolinoyl hydrazone

AU Modi, Chetan K.; Thaker, B. T.

CS Department of Chemistry, Veer Narmad South Gujarat University, Surat, 395 007, India

SO Asian Journal of Chemistry (2005), 17(1), 581-586

CODEN: AJCHEW; ISSN: 0970-7077


PB Asian Journal of Chemistry

DT Journal

LA English

OS CASREACT 143:108428

GI




AB The ligand 5-hydroxy-3-methyl-1-phenyl-4-propionylpyrazole  
picolinoylhydrazone (PMHPPr-PHz) (I) was synthesized by condensing  
3-methyl-1-phenyl-4-propionyl-5-pyrazolone with 2-picolinic acid  
hydrazide. The complexes of PMHPPr-PHz with La(III), Ce(III), Nd(III),  
Sm(III), Gd(III), Dy(III) and Er(III) ions were synthesized. The compns.  
and properties of the ligand and its complexes were established by  
elemental analyses, magnetic measurements, molar conductance, IR, <sup>1</sup>H NMR,  
electronic spectra and thermal analyses.

IT 856655-93-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of hydroxypropionylpyrazole picolinoylhydrazone and  
complexation to give rare earth complexes)

RN 856655-93-1 CAPLUS

CN 2-Pyridinecarboxylic acid, [1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-  
yl)propylidene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 18 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:369687 CAPLUS <<LOGINID::20070702>>

DN 141:359812

TI Synthesis and Crystal Structure of Mixed-Ligand Ni(II) Complex of  
N-(1-Phenyl-3-methyl-4-benzylidene-5-pyrazolone) p-Nitrobenzoylhydrazide  
and Pyridine

AU Zhang, Li; Liu, Lang; Jia, Dianzeng; Yu, Kaibei

CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop.  
Rep. China

SO Structural Chemistry (2004), 15(4), 327-331  
CODEN: STCHES; ISSN: 1040-0400

PB Kluwer Academic/Plenum Publishers

DT Journal

LA English

OS CASREACT 141:359812

AB A novel mixed-ligand Ni complex, [Ni(PMBP-PNH)(Py)<sub>3</sub>], [PMBP-PNH =  
N-(1-phenyl-3-methyl-4-benzylidene-5-pyrazolone) p-nitrobenzoylhydrazide;  
Py = pyridine], was synthesized by the hydrothermal method and  
characterized by elemental anal., IR spectrum, thermal anal., and




single-crystal x-ray diffraction. The x-ray diffraction reveals that the Ni (II) ion in the title complex is in a slightly distorted octahedral arrangement of the ONO donor atoms of primary ligand PMBP-PNH and three N-donor atoms in the secondary ligand pyridine.

IT 777063-77-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(complexes with nickel(II))

RN 777063-77-1 CAPLUS

CN Benzoic acid, 4-nitro-, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 19 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:288137 CAPLUS <<LOGINID::20070702>>

DN 141:270398

TI Complexes of nickel(II) with 2,3-dimethyl-4-(benzoylhydrazidomethylene)-1-phenyl-3-pyrazolin-5-one

AU Raju, K. C.; Radhakrishnan, P. K.

CS Sch. of Chem. Sci., Mahatma Gandhi Univ., Kottayam, Kerala, India

SO Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry (2004), 34(3), 417-428

CODEN: SRIMCN; ISSN: 0094-5714

PB Marcel Dekker, Inc.

DT Journal

LA English

OS CASREACT 141:270398


AB Ni(II) complexes of the Schiff base 2,3-dimethyl-4-(benzoylhydrazidomethylene)-1-phenyl-3-pyrazolin-5-one (L) [Ni(L)2(ClO4)]ClO4, [Ni(L)2(NO3)](NO3), and [Ni(L)2X2] (X = Cl, Br, or I) were synthesized and characterized by elemental analyses, elec. conductance in nonaq. solvents, IR and electronic spectra as well as magnetic susceptibility measurements. In these complexes, L acts as a neutral bidentate ligand coordinating through the azomethine N and the carbonyl O of the pyrazolone ring. In the perchlorate and nitrate complexes one of the anions is coordinated to the metal ion in a bidentate fashion while in the halide complexes both the anions are coordinated. An octahedral geometry is assigned around the Ni(II) ion in all these complexes.

IT 76644-54-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(complexation with nickel salts)

RN 76644-54-7 CAPLUS

CN Benzoic acid, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 20 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:105308 CAPLUS <<LOGINID::20070702>>

DN 140:406766

TI Syntheses and crystal structures of derivatives of pyrazolone with  
two-different configurations

AU Liu, Lang; Jia, Dian-Zeng; Yu, Kai-Bei

CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop.  
Rep. China

SO Jiegou Huaxue (2004), 23(1), 112-118

CODEN: JHUADF; ISSN: 0254-5861

PB Jiegou Huaxue Bianji Weiyuanhui

DT Journal

LA Chinese

OS CASREACT 140:406766


AB 5-Hydroxy-3-methyl-1-phenylpyrazol-4-yl Ph ketone (PMBP) and  
Picolinoylhydrazine (PCH) or Isonicotinohydrazide (INTH) reacted to form  
the corresponding pyrazolone derivative PMBP-PCH and PMBP-INTH; their crystal  
structures were determined by X-ray single-crystal diffraction. The crystal  
structure of PMBP-PCH belongs to triclinic, space group P1 with a =  
7.783(2), b = 10.993(3), c = 12.621(3) Å, α = 92.96(2), β =  
103.87(2), γ = 101.54(2)°, V = 1021.5(5) Å<sup>3</sup>, Z = 2, Dc =  
1.307 g/cm<sup>3</sup>, μ(MoKα) = 0.088 mm<sup>-1</sup>, F(000) = 421, R = 0.0436 and  
wR = 0.0937. The dimer was formed through intermol. hydrogen bonds. The  
crystal structure of PMBP-INTH is of monoclinic, space group P21/c with a  
= 14.083(4), b = 13.865(3), c = 10.609(2) Å, β =  
101.66(2)°, V = 2028.8(8) Å<sup>3</sup>, Z = 4, Dc = 1.301 g/cm<sup>3</sup>,  
μ(MoKα) = 0.087 mm<sup>-1</sup>, F(000) = 832, R = 0.0473 and wR = 0.0898.  
The intermol. proton transfer leads to the formation of zwitterionic  
structure (PMBP-INTH), in which the N(2) and N(1) atoms are the centers of  
neg. and pos. charges, resp.

IT 191219-04-2P 508167-98-4P


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(pyrazolone derivative synthesis and crystal structure configuration)

RN 191219-04-2 CAPLUS

CN 4-Pyridinecarboxylic acid, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



RN 508167-98-4 CAPLUS  
 CN 2-Pyridinecarboxylic acid, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)




L13 ANSWER 21 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:761720 CAPLUS <<LOGINID::20070702>>  
 DN 140:163758  
 TI Synthesis and crystal structure of N-(1-phenyl-3-methyl-4-benzal-pyrazolone-5)-furoic hydrazide  
 AU Liu, Lang; Ji, Ya-Li; Jia, Dian-Zeng; Yu, Kai-Bei  
 CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop. Rep. China  
 SO Jiegou Huaxue (2003), 22(5), 568-572  
 CODEN: JHUADF; ISSN: 0254-5861  
 PB Jiegou Huaxue Bianji Weiyuanhui  
 DT Journal  
 LA English  
 OS CASREACT 140:163758

AB N-(1-Phenyl-3-methyl-4-benzal-pyrazolone-5)-furoic hydrazide (C22H18N4O3, CCDC No: 188946) was synthesized and characterized by IR spectrum, 1H NMR and single-crystal X-ray diffraction. The crystal is of orthorhombic, space group Pbca with a = 11.870(2), b = 15.951(3), c = 19.674(3) Å, V = 3725.0(11) Å<sup>3</sup>, Mr = 386.40, Z = 8, Dc = 1.378 g/cm<sup>3</sup>, F(000) = 1616, R = 0.0455 and wR = 0.0809. The inter- or intramol. hydrogen bonds result in the formation of three-dimensional network structure.

IT 654663-70-4P  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (mol. and crystal structure; preparation and crystal structure of N-(1-phenyl-3-methyl-4-benzal-pyrazolone-5)-furoic hydrazide by reaction of 1-phenyl-3-methyl-4-benzoyl-pyrazolone-5 with furoic hydrazide)

RN 654663-70-4 CAPLUS

CN 2-Furancarboxylic acid, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 22 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:754447 CAPLUS <<LOGINID::20070702>>

DN 140:303580

TI Synthesis, characterization and bacteriostatic activity of compound derived from PMTFP and salicylic hydrazide

AU Zhang, Shu-ming; Jia, Yong-jin; Wang, Jin-ling; Miao, Fang-ming

CS College of Chemistry and Life Science, Tianjin Normal University, Tianjin, 300074, Peop. Rep. China

SO Tianjin Shifan Daxue Xuebao, Ziran Kexueban (2003), 23(2), 4-6  
 CODEN: TSDXAD; ISSN: 1671-1114

PB Tianjin Shifan Daxue Xuebao, Ziran Kexueban Bianjibu

DT Journal

LA Chinese


OS CASREACT 140:303580

AB A Schiff base derived from 1-phenyl-3-methyl-4-trifluoroacetyl-5-pyrazolone (PMTFP) and salicylic hydrazide have been synthesized and characterized by IR and UV. This compound showed good inhibiting activities for both Gram-pos. bacteria-Staphylococcus aureus and Gram-neg. bacteria-Escherichia coli.


IT 676481-96-2P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and bacteriostatic activities of Schiff base from PMTFP and salicylic hydrazide)

RN 676481-96-2 CAPLUS

CN Benzoic acid, 2-hydroxy-, [1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)-2,2,2-trifluoroethylidene]hydrazide (9CI) (CA INDEX NAME)




L13 ANSWER 23 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:715166 CAPLUS <<LOGINID::20070702>>  
 DN 140:209355  
 TI Complexes of Copper(II) with 2,3-Dimethyl-4-formyl(benzhydrazone)-1-phenyl-3-pyrazolin-5-one  
 AU Raju, K. C.; Radhakrishnan, P. K.  
 CS School of Chemical Sciences, Mahatma Gandhi University, Kerala, India  
 SO Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry (2003), 33(8), 1307-1318  
 CODEN: SRIMCN; ISSN: 0094-5714  
 PB Marcel Dekker, Inc.  
 DT Journal  
 LA English  
 OS CASREACT 140:209355  
 GI



I


AB Copper(II) complexes of the Schiff base 2,3-dimethyl-4-formyl(benzhydrazone)-1-phenyl-3-pyrazolin-5-one (L = I) [Cu(L)2]X2 (X = ClO4 or NO3), [Cu(L)Cl2] and [Cu(L)2Br2] were synthesized and characterized by elemental analyses, molar conductance in nonaq. solvents, IR, electronic and EPR spectra, as well as magnetic susceptibility measurements. In these complexes, the ligand acts as a neutral bidentate unit coordinating through the azomethine nitrogen atom and the carbonyl oxygen of the pyrazolone ring. In the perchlorate and nitrate complexes both anions remain ionic, while in the corresponding halide complexes both anions are coordinated to the metal ion. The perchlorate, nitrate and chloride complexes are of square-planar geometry while the bromide complex is of distorted octahedral geometry.  
 IT 76644-54-7  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant for preparation of copper(II) formylpyrazolinone benzoylhydrazone complexes)

RN 76644-54-7 CAPLUS  
 CN Benzoic acid, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 24 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:483572 CAPLUS <<LOGINID::20070702>>  
 DN 139:245944  
 TI Synthesis and crystal structure of supramolecular compound of  
 4-(a'-hydroxybenzoylhydrazinyl)benzal/ethylidene-5-methyl-2-phenyl-2,4-  
 dihydropyrazol-3-one  
 AU Liu, Lang; Ji, Ya-Li; Jia, Dian-Zeng; Yu, Kai-Bei  
 CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop.  
 Rep. China  
 SO Huaxue Xuebao (2003), 61(6), 893-900  
 CODEN: HHHPA4; ISSN: 0567-7351  
 PB Kexue Chubanshe  
 DT Journal  
 LA Chinese  
 OS CASREACT 139:245944  
 GI



I

AB The synthesis and crystal structure of title compds. I (R = Ph, Me) are  
 presented in this paper. The crystal structures were determined by X-ray  
 single crystal diffraction study. Crystal structure of I (R = Ph) belongs  
 to monoclinic system with space group C2/c. The unit cell parameters are  
 a = 1.4201(2) nm, b = 1.65542(2) nm, c = 1.8455(3) mn,  $\beta$  =  
 10132(1)°, V = 4.2541(10) nm<sup>3</sup>, Z = 8, Dc = 1.344 g/cm<sup>3</sup>,  $\mu$  =  
 0.094 mm<sup>-1</sup>, F(000) = 1808, R = 0.0442, wR = 0.1037. The water mols.  
 bridge the adjacent stacks by the hydrogen bonds leading to the formation  
 of supramol. compound with two-dimensional network structure along the ac  
 side. The crystal structure of II (R = Me) belongs to triclinic system  
 with space group P.hivin.1. The unit cell parameters are a = 1.2120(2)  
 nm, b = 1.2223(2) nm, c = 1.4159(3) nm,  $\alpha$  = 70.38(1)°,  $\beta$   
 = 74.91(1)°,  $\gamma$  = 63.64(1)°, V = 1.7549(5) nm<sup>3</sup>, Z = 4,  
 Dc = 1.326 g/cm<sup>3</sup>,  $\mu$  = 0.092 mm<sup>-1</sup>, F(000) = 736, R = 0.0436, wR =  
 0.1076. The supramol. with one dimensional chain structure was formed

through hydrogen bonds along the a axis. The mols. piled the layered structure along the b axis due to intermol. interactions.


IT 599166-78-6P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis and crystal structure of supramol. compound of  
hydroxybenzoylhydrazinylbenzalidenemethylphenyldihydropyrazolone)

RN 599166-78-6 CAPLUS

CN Benzoic acid, 2-hydroxy-, (2E)-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 599166-81-1P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis and crystal structure of supramol. compound of  
hydroxybenzoylhydrazinylethylidenemethylphenyldihydropyrazolone)

RN 599166-81-1 CAPLUS

CN Benzoic acid, 2-hydroxy-, (2E)-[1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)ethylidene]hydrazide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L13 ANSWER 25 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:259127 CAPLUS <<LOGINID::20070702>>

DN 139:62054

TI Synthesis, characterization and crystal structure of mixed-ligand complex  
[Ni(PMBP-sal)(py)]

AU Ji, Ya-Li; Liu, Lang; Jia, Dian-Zeng; Yu, Kai-Bei

CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop.  
Rep. China

SO Wujia Huaxue Xuebao (2003), 19(4), 345-349

CODEN: WHUXEO; ISSN: 1001-4861

PB Wujia Huaxue Xuebao Bianjibu

DT Journal

LA English

OS CASREACT 139:62054

AB A new mixed-ligand Ni(II) complex, [Ni(PMBP-sal)(py)], (PMBP-sal =

1-phenyl-3-methyl-4-benzylidene-pyrazolone-5 salicylhydrazone; py = pyridine), was synthesized and characterized by elemental anal., IR spectrum, UV-visible spectrum, cyclic voltammogram and single crystal x-ray diffraction. It crystallizes in the monoclinic system, space group P21/c. The lattice parameters are: a 1.3544(3), b 1.7225(5), c 1.0937(2) nm,  $\beta$  102.57(2)°, V = 2.4904(10) nm<sup>3</sup>,  $d_c$  = 1.462 g m<sup>-3</sup>, Z = 4. The coordination geometry around Ni(II) in the ternary mixed-ligand complex is slightly distorted four-coordinated square-planar geometry, in which the primary ligand PMBP-sal participates in coordination with ONO donor atoms and the secondary ligand pyridine is N-bonded.


IT 387829-06-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(for preparation of nickel benzylidenepyrazolone salicylhydrazone complex)

RN 387829-06-3 CAPLUS

CN Benzoic acid, 2-hydroxy-, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylen]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 26 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:3204 CAPLUS <<LOGINID::20070702>>

DN 138:313316

TI Synthesis and characterization of lanthanide complexes of 1-phenyl-3-methyl-5-hydroxy-4-pyrazolyl-phenyl ketone-2'-picolinoyl hydrazone

AU Thaker, B. T.; Modi, Chetan K.

CS Department of Chemistry, S G University, Surat, 395 007, India

SO Indian Journal of Chemistry, Section A: Inorganic, Bio-inorganic, Physical, Theoretical & Analytical Chemistry (2002), 41A(12), 2544-2547  
CODEN: ICACEC; ISSN: 0376-4710

PB National Institute of Science Communication

DT Journal

LA English

OS CASREACT 138:313316

AB The ligand, 1-phenyl-3-methyl-5-hydroxy-4-pyrazolyl Ph ketone 2'-picolinoyl hydrazone (HL) was prepared by condensation of 1-phenyl-3-methyl-4-benzoyl-5-pyrazolone with 2-picolinic acid hydrazide. Seven complexes of lanthanides with HL [Ln(HL)<sub>3</sub>].2H<sub>2</sub>O (Ln = trivalent lanthanides such as La, Ce, Nd, Sm, Gd, Dy and Er) were synthesized and characterized by complexometric titration of lanthanoid ions, elemental anal., molar conductance, IR, <sup>1</sup>H NMR, electronic spectral studies and TGA anal. IR spectra and thermogram shows two H<sub>2</sub>O moieties outside the coordination sphere and are nonelectrolytic in nature. The complexes appear to be nine-coordinated and ligand act as a tridentate ligand.


IT 508167-98-4P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and complexation with lanthanides)

RN 508167-98-4 CAPLUS

CN 2-Pyridinecarboxylic acid, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 27 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:745493 CAPLUS <<LOGINID::20070702>>

DN 138:255147

TI Synthesis and crystal structure of N-(1-phenyl-3-methyl-4-benzylidene-5-pyrazolone) p-nitrobenzoylhydrazide

AU Ji, Ya-Li; Liu, Lang; Jia, Dian-Zeng; Yu, Kai-Bei

CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop. Rep. China

SO Jiegou Huaxue (2002), 21(5), 553-556

CODEN: JHUADF; ISSN: 0254-5861

PB Jiegou Huaxue Bianji Weiyuanhui

DT Journal

LA Chinese

OS CASREACT 138:255147


AB Title compound was synthesized from the condensation of 1-Phenyl-3-methyl-4-benzoyl-2-pyrazolin-5-one and p-nitrobenzoylhydrazine, giving the product with 70% yield. The crystal structure was determined by x-ray diffraction. The crystal belongs to the monoclinic system, space group P21/n with cell parameters: a = 9.151(2), b = 18.405(5), c = 13.061(3) Å, β = 101.12(1)°, V = 2158.5(9) Å<sup>3</sup>, Z = 4, D<sub>c</sub> = 1.358 g/cm<sup>3</sup>, μ = 0.096 mm<sup>-1</sup> and F(000) = 920. The final R = 0.0468 and wR = 0.1090 for 2116 observed reflections with I > 2σ(I). The dimer was formed through intermol. hydrogen bonds.

IT 502968-21-0P


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(crystal structure and synthesis of)

RN 502968-21-0 CAPLUS

CN Benzoic acid, 4-nitro-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)




L13 ANSWER 28 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:556743 CAPLUS <<LOGINID::20070702>>  
 DN 137:288054  
 TI Synthesis, characterization, and biological activity of rare earth  
 complexes of 1-phenyl-3-methyl-4-benzoyl-5-pyrazolone benzoylhydrazone  
 AU Yang, Zheng-Yin  
 CS Chemistry and Engineering College, Lanzhou University, Lanzhou, 730000,  
 Peop. Rep. China  
 SO Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry (2002),  
 32(5), 903-912  
 CODEN: SRIMCN; ISSN: 0094-5714  
 PB Marcel Dekker, Inc.  
 DT Journal  
 LA English  
 OS CASREACT 137:288054  
 AB 1-Phenyl-3-methyl-4-benzoyl-5-pyrazolone benzoylhydrazone (H2L) was prepared  
 by condensation of 1-phenyl-3-methyl-4-benzoyl-5-pyrazolone with  
 benzoylhydrazine. Six rare earth complexes of H2L were synthesized and  
 characterized from elemental analyses, IR, UV, <sup>1</sup>H NMR spectra and thermal  
 analyses. The general formula of the complexes is Ln(HL)3·3H2O  
 (Ln(III) = La, Pr, Nd, Eu, Gd and Er). In addition, the suppression ratio  
 (η<sub>r</sub>) for O<sub>2</sub>·<sup>-</sup> radicals as well as the inhibitory ratio (η<sub>1</sub>)  
 for lipid peroxidn. were determined by an UV spectral method. The results show  
 that η<sub>r</sub> and η<sub>1</sub> of the complexes are .apprx.39-51% and 20-39% resp.  
 For the ligand, η<sub>r</sub> = 36% η<sub>1</sub> = 18%.  
 IT 183113-24-8P  
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN  
 (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation, complexation with rare earth ions, IR and UV-visible spectra,  
 thermal decomposition, superoxide radical scavenger and inhibition of lipid  
 peroxidn. in rabbit liver)  
 RN 183113-24-8 CAPLUS  
 CN Benzoic acid, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-  
 yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 29 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:448805 CAPLUS <<LOGINID::20070702>>  
DN 137:178904  
TI Yttrium and lanthanide nitrate complexes of 2,3-dimethyl-4-formyl(benzhydrazide)-1-phenyl-3-pyrazoline-5-one  
AU Ajithkumar, G.; Radhakrishnan, P. K.  
CS School of Chemical Sciences, Mahatma Gandhi University, Kottayam, 686560, India  
SO Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry (2002), 32(4), 831-842  
CODEN: SRIMCN; ISSN: 0094-5714  
PB Marcel Dekker, Inc.  
DT Journal  
LA English  
OS CASREACT 137:178904  
GI



I


AB Complexes of yttrium and lanthanide nitrates with the Schiff base 2,3-dimethyl-4-formyl(benzhydrazide)-1-phenyl-3-pyrazoline-5-one (I, L) were synthesized and characterized by elemental analyses, elec. conductance in nonaq. solvents and electronic as well as IR spectra. The complexes have the general mol. formulas  $[Ln(L)_2(NO_3)](NO_3)_2$  ( $Ln = Y, La, Pr, Nd, Sm, Eu, Gd, Dy, Ho$  or  $Er$ ). The ligand chelates with the metal ion in a neutral tridentate fashion through both carbonyl oxygens and the azomethine nitrogen in all of these complexes. One of the nitrate ions is monodentately coordinated and the other two remain as counterions. A coordination number of seven is assigned to the metal in all of these complexes. The covalency parameters evaluated from solid and solution phase electronic spectra suggest weak covalent character of the metal-ligand bond.  
IT 76644-54-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and IR spectra of yttrium and rare earth nitrate complexes of antipyrinecarboxaldehyde benzhydrazide Schiff base)  
RN 76644-54-7 CAPLUS  
CN Benzoic acid, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-

yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 30 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:448799 CAPLUS <<LOGINID::20070702>>  
DN 137:194495  
TI Synthesis and characterization of metal complexes of N-(1-phenyl-3-methyl-4-benzal-5-pyrazolone)-p-methoxybenzoylhydrazine  
AU Liu, Lang; Jia, Dianzeng; Ji, Yali  
CS Institute of Applied Chemistry, Xinjiang University, Urumqi, 830046, Peop. Rep. China  
SO Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry (2002), 32(4), 739-751  
CODEN: SRIMCN; ISSN: 0094-5714  
PB Marcel Dekker, Inc.  
DT Journal  
LA English  
OS CASREACT 137:194495  
GI



I


AB A new tridentate ligand (I) with ONO donor atoms and its complexes were prepared and characterized from elemental analyses, IR, UV spectra, thermal analyses and cyclic voltammetry. Spectral data show that the complexes conform to the general exptl. formula  $ML_2 \cdot nH_2O$  [ $M = Mn(II), Co(II), Ni(II), Zn(II), Cd(II)$ ;  $HL = N-(1-phenyl-3-methyl-4-benzal-5-pyrazolone)-p-methoxybenzoylhydrazine$  (I)].  
IT 382594-33-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and IR spectra and thermal decomposition of transition metal complexes of (phenyl(methyl)benzalpyrazolone)methoxybenzoylhydrazine)  
RN 382594-33-4 CAPLUS  
CN Benzoic acid, 4-methoxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)




✓ #31

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 31 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2001:769894 CAPLUS <<LOGINID::20070702>>  
DN 136:53709  
TI Synthesis and crystal structure of the derivatives of hydrazide containing pyrazolone  
AU Liu, Lang; Jia, Dian-Zeng; Qiao, Yong-Min; Yu, Kai-Bei  
CS Institute of Applied Chemistry, Xinjiang University, Wulumuqi, 830046, Peop. Rep. China  
SO Huaxue Xuebao (2001), 59(9), 1495-1501  
CODEN: HHHPA4; ISSN: 0567-7351  
PB Kexue Chubanshe  
DT Journal  
LA Chinese  
OS CASREACT 136:53709  
AB The synthesis and crystal structure of PMBP-NTH (PMBP = 1-phenyl-3-methyl-4-benzoyl-5-pyrazolinone, NTH = nicotinoyl hydrazine) and PMBP-PAH (PAH = p-methoxybenzoyl hydrazine) are presented in this paper. The crystal structures were determined by x-ray single crystal diffraction. Crystal structure of PMBP-NTH belongs to triclinic system with space group P. The unit cell parameters are a = 0.9024(2) nm, b = 1.0953(2) nm, c = 1.1635(2) nm,  $\alpha = 67.070(10)^\circ$ ,  $\beta = 68.220(10)^\circ$ ,  $\gamma = 84.770(10)^\circ$ , V = 0.9816(3) nm<sup>3</sup>, Z = 2, D<sub>0</sub> = 1.345 g/cm<sup>3</sup>,  $\mu = 0.090$  mm<sup>-1</sup>, F(000) = 416. The crystal structure of PMBP-PAH belongs to monoclinic system with space group P2<sub>1</sub>/c. The unit cell parameters are a = 1.2715(4) nm, b = 0.9171(10) nm, c = 1.8979(3) nm,  $\beta = 106.890(10)^\circ$ , V = 2.1177(8) nm<sup>3</sup>, Z = 4, D<sub>0</sub> = 1.338 g/cm<sup>3</sup>,  $\mu = 0.090$  mm<sup>-1</sup>, F(000) = 896, R = 0.0414, wR = 0.0972.  
IT 331238-77-8P 382594-33-4P  
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (synthesis and crystal structure of the derivs. of hydrazide containing pyrazolone)  
RN 331238-77-8 CAPLUS  
CN 3-Pyridinecarboxylic acid, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)



RN 382594-33-4 CAPLUS  
 CN Benzoic acid, 4-methoxy-, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)phenylmethyl]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 32 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:478008 CAPLUS <<LOGINID::20070702>>  
 DN 136:128052  
 TI Synthesis and antioxidative activity of rare earth complexes of PMBP-benzoyl hydrazone  
 AU Yang, Zhengyin; Yang, Rudong  
 CS Chemistry and Engineering College, Lanzhou University, Lanzhou, 730000, Peop. Rep. China  
 SO Chemical Journal on Internet [online computer file] (2001), 3(4), No pp. given  
 CODEN: CJIHAC; ISSN: 1523-1623  
 URL: <http://www.chemistrymag.org/cji/2001/034018pc.htm>  
 PB Chemical Journal on Internet  
 DT Journal; (online computer file)  
 LA Chinese  
 AB 1-Phenyl-3-methyl-5-hydroxy-4-pyrazolyl Ph ketone benzoylhydrazone (H2PBB) was prepared by condensation of 1-phenyl-3-methyl-4-benzoyl-5-pyrazolone

with benzoylhydrazine. Six complexes of rare earths with H<sub>2</sub>PBB were synthesized and characterized from elemental analyses, IR, UV, <sup>1</sup>H NMR spectra and thermal analyses. The general formula of the complexes is RE(HPBB)<sub>3</sub>·3H<sub>2</sub>O (RE(III) = La, Pr, N, Eu, Gd and Er). Also, the scavenger effects on O<sub>2</sub>•- radicals of the ligand and its complexes were determined


IT 183113-24-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and complexation with rare earths)

RN 183113-24-8 CAPLUS

CN Benzoic acid, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 33 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:23256 CAPLUS <<LOGINID::20070702>>

DN 134:231083

TI Crystal structure and antitumor activity of some rare earth metal complexes with Schiff base

AU Yang, Z.-Y.; Yang, R.-D.; Li, F.-S.; Yu, K.-B.

CS Department of Chemistry, Lanzhou University, Lanzhou, 730000, Peop. Rep. China

SO Polyhedron (2000), 19(26-27), 2599-2604

CODEN: PLYHDE; ISSN: 0277-5387

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 134:231083

AB The ligand 1-phenyl-3-methyl-5-hydroxy-4-pyrazolyl Ph ketone (PMBP) isonicotinoyl hydrazone (H<sub>2</sub>L) was prepared by condensation of PMBP with isoniazid. Ln(HL)<sub>3</sub>·3.5H<sub>2</sub>O (Ln = La, Eu, Gd, Tb, Dy, Ho and Er) were synthesized and characterized from elemental analyses, IR, UV, <sup>1</sup>H NMR spectra and thermal analyses. X-ray diffraction anal. showed that the coordination polyhedron of the Eu complex is a tricapped trigonal prism. The La and Eu complexes possess antitumor activity, and the inhibitory rates for leukemia cells (L1210) are 87.1% and 78.5%, resp.


IT 329247-15-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation and complexation with lanthanides and antitumor activity)

RN 329247-15-6 CAPLUS


CN 4-Pyridinecarboxylic acid, 2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 34 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2000:633056 CAPLUS <<LOGINID::20070702>>  
DN 133:328818  
TI Synthesis, characterization and scavenger effects on O<sub>2</sub>-• of 3d transition metal complexes of isonicotinoyl hydrazone derived from isoniazid with PMBP  
AU Yang, Zheng-Yin  
CS Department of Chemistry, Lanzhou University, Lanzhou, 730000, Peop. Rep. China  
SO Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry (2000), 30(7), 1265-1271  
CODEN: SRIMCN; ISSN: 0094-5714  
PB Marcel Dekker, Inc.  
DT Journal  
LA English  
OS CASREACT 133:328818  
AB The 3d transition metal complexes of isonicotinoyl hydrazone derived from isoniazid with 1-phenyl-3-methyl-4-benzoyl-5-pyrazolone (PMBP) were synthesized and characterized from elemental analyses, IR, UV spectra and thermal analyses. The general formula of the complexes is ML·nH<sub>2</sub>O (M(II) = Cr, Mn, Fe, Co, Ni and Cu, n = 0, 1). The complexes possess certain scavenger effects on O<sub>2</sub>-• radicals.  
IT 191219-04-2  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(complexation with first-row transition metals, thermal decomposition, and scavenger effect on superoxide radical anion)  
RN 191219-04-2 CAPLUS  
CN 4-Pyridinecarboxylic acid, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)






RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 35 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2000:431992 CAPLUS <<LOGINID::20070702>>  
DN 133:237910  
TI Synthesis of novel benzoquinone and hydroquinone derivatives bearing  
different heterocyclic systems as potential antimicrobial agents  
AU Chaaban, I.; Bekhit, A. A.; Abdet-Ghany, Y. S.  
CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of  
Alexandria, Alexandria, Egypt  
SO Egyptian Journal of Pharmaceutical Sciences (1999), Volume Date 1998,  
39(1-3), 91-107  
CODEN: EJPSBZ; ISSN: 0301-5068  
PB National Information and Documentation Centre  
DT Journal  
LA English  
AB Hydroquinonecarbonyl and benzoquinonecarbonyl derivs. of  
aminothiazolidinones and pyrazolidinediones were prepared Th compds. showed  
good to excellent antibacterial and antifungal activity with the  
hydroquinones showing better activity than the benzoquinones.  
IT 131624-94-7P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(benzoquinone and hydroquinonecarbonyl derivs. of aminothiazolidinones  
and pyrazolidinediones as fungicides and bactericides)  
RN 131624-94-7 CAPLUS  
CN Benzoic acid, 2,5-dihydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-  
pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 36 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2000:320287 CAPLUS <<LOGINID::20070702>>  
DN 133:142514  
TI Synthesis, structure and properties of a novel kind of photochromic compound containing a pyrazolone-ring  
AU Tang, X.-c.; Jia, D.-z.; Liang, K.; Zhang, X.-g.; Xia, X.; Zhou, Z.-y.  
CS Institute of Applied Chemistry, Xinjiang University, Urumgi, 830046, Peop. Rep. China  
SO Journal of Photochemistry and Photobiology, A: Chemistry (2000), 134(1-2), 23-29  
CODEN: JPPCEJ; ISSN: 1010-6030  
PB Elsevier Science S.A.  
DT Journal  
LA English  
AB Two new organic photochromic compds. containing pyrazolone-ring as photochromic functional unit: 1-phenyl-3-methyl-4-benzoylpyrazol-5-one thiosemicarbazone (1A) and 1-phenyl-3-methyl-4-benzoylpyrazol-5-one S-methylthiosemicarbazone (2A), and some analogous non-photochromic derivs. were synthesized and characterized by elemental anal., MS, IR Spectra, NMR spectra. The photochromic properties and photocolored kinetics of 1A and 2A were studied by powder-UV reflectance spectra under irradiation of 293 nm light. The crystal structure anal. of photocolored product of 1A showed the photochromic phenomenon was due to the photoisomerization from enol form to keto form. With the addition of the anal. of IR spectra, an intermol. proton transfer mechanism of the photochem. process was proposed.  
IT 286966-14-1P  
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (synthesis and structure and properties of novel photochromic compds. containing pyrazolone-ring)  
RN 286966-14-1 CAPLUS  
CN 3-Pyridinecarboxylic acid, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylenel]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 37 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2000:250982 CAPLUS <<LOGINID::20070702>>  
DN 133:43738  
TI Some heterocycles from dehydro-L-ascorbic acid and dehydro-D-isoascorbic acid  
AU El-Sekily, M. A.; Elba, M. E.; Fouad, F. S.  
CS Department of Chemistry, Faculty of Science, Alexandria, Egypt  
SO Journal of the Indian Chemical Society (2000), 77(3), 168-171  
CODEN: JICSAH; ISSN: 0019-4522  
PB Indian Chemical Society  
DT Journal  
LA English  
OS CASREACT 133:43738  
GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Reaction of D-erythro-2,3-hexodiulosono-1,4-lactone-2-phenylhydrazine with p-sulfamylphenylhydrazine gives the 3-p-sulfamylphenylhydrazine, which upon treatment with hydrazine hydrate or CuCl<sub>2</sub> affords pyrazolinedione (I) or 3,6-anhydro derivative (II), resp. Condensation of 3-carboxaldehyde-1-p-nitrophenyl-4,5-pyrazolinedione-4-phenylhydrazine with thiosemicarbazide or hydroxylamine produces 3-carboxaldehydethiosemicarbazone or hydroxyiminomethyl derivative, which reacts with BzCl to give the bicyclic (III). Reaction of 2-phenyl-2,6-dihydro-6-(1,2-diacetoxyethyl)-4H-furo[3,4-d]-1,2,3-triazol-4-one with hydrazine hydrate gives carboxylic acid hydrazide which upon treatment with some carbonyl compds. or CS<sub>2</sub> yields acylhydrazones or binuclear heterocycle (IV). Acetylation gives the corresponding acetylated derivs. or produces the corresponding cyclized derivs. (V) (R = H, Me; Ar = Ph, 4-O<sub>2</sub>N-C<sub>6</sub>H<sub>4</sub>).

IT 274905-11-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(synthesis of heterocycles from dehydro-L-ascorbic acid and dehydro-D-isoascorbic acid)

RN 274905-11-2 CAPLUS  
CN 2H-1,2,3-Triazole-4-carboxylic acid, 2-phenyl-5-[(1S,2S)-1,2,3-trihydroxypropyl]-, [[(4Z)-4,5-dihydro-5-oxo-1-phenyl-4-(phenylhydrazono)-1H-pyrazol-3-yl]methylene]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as described by E or Z.



RE.CNT 7      THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 38 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:397267 CAPLUS <<LOGINID::20070702>>

DN 131:193889

TI Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target

AU Sausville, Edward A.; Zaharevitz, Daniel; Gussio, Robert; Meijer, Laurent; Louarn-Leost, Maryse; Kunick, Conrad; Schultz, Robert; Lahusen, Tyler; Headlee, Donna; Stinson, Sherman; Arbuck, Susan G.; Senderowicz, Adrian

CS Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA

SO Pharmacology & Therapeutics (1999), 82(2-3), 285-292

CODEN: PHTHDT; ISSN: 0163-7258


PB Elsevier Science Inc.

DT Journal

LA English

AB Cyclin-dependent kinases (CDKs) have been recognized as key regulators of cell cycle progression. Alteration and deregulation of CDK activity are pathogenic hallmarks of neoplasia. Therefore, inhibitors or modulators would be of interest to explore as novel therapeutic agents in cancer, as well as other hyperproliferative disorders. Flavopiridol is a semisynthetic flavonoid that emerged from an empirical screening program as a potent antiproliferative agent that mechanistic studies demonstrated to directly inhibit CDKs 1, 2, and 4 as a competitive ATP site antagonist. Initial clin. trials have shown that concns. that inhibit cell proliferation and CDK activity in vitro can be safely achieved in humans, and addnl. clin. trials will establish its clin. potential. To address the need for addnl. chemotypes that may serve as lead structures for drugs that would not have the toxicities associated with flavopiridol, compds. with a similar pattern of cell growth inhibitory activity in the National Cancer Institute's in vitro anticancer drug screen have been recognized by the computer-assisted pattern recognition algorithm COMPARE and then screened for anti-CDK activity in a biochem. screen. The benzodiazepine derivative NSC 664704 (7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one) was revealed by that approach as a moderately potent (IC50 0.4 μM) inhibitor of CDK2, which in initial expts. shows evidence of causing cell cycle redistribution in living cells. NSC 664704 is, therefore, a candidate for further structural optimization, guided in part by understanding of the ATP-binding site in CDK2. This approach represents one way of combining empirical screening information with structure-based design to derive novel candidate therapeutic agents directed against an important cellular target.

IT 101868-30-8, NSC 651704  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target)  
 RN 101868-30-8 CAPLUS  
 CN Benzoic acid, 3,5-dibromo-2-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 39 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1999:315293 CAPLUS <<LOGINID::20070702>>  
 DN 131:27080  
 TI Ligand exchange reactions of  $\text{ReOCl}_3(\text{PPh}_3)_2$  with tridentate diacidic ligands with the donor set O.intrsec.N.intrsec.O(N): molecular and electronic structures of the resulting oxo-rhenium(V) complexes  
 AU Sawusch, S.; Jager, N.; Schilde, U.; Uhlemann, E.  
 CS Institute for Inorganic Chemistry and Chemical Education, University of Potsdam, Potsdam, D-14415, Germany  
 SO Structural Chemistry (1999), 10(2), 105-119  
 CODEN: STCHES; ISSN: 1040-0400  
 PB Kluwer Academic/Plenum Publishers  
 DT Journal  
 LA English  
 AB Oxo-Re complexes  $\text{ReO}(\text{LLL})(\text{LLLH})$  with tridentate diacidic ligands (LLLH2) containing the donor set O.intrsec.N.intrsec.O(N) were synthesized and characterized. X-ray analyses were carried out for benzoylacetone-2-hydroxyanilato(2-)-benzoylacetone-2-hydroxyanilato-oxo-Re(V)  $\text{ReO}(\text{BAHA})_2$  (1), [2,6-diphenylacetylpyridinato(2-)]-2,6-diphenylacetylpyridinato-oxo-Re(V)  $\text{ReO}(\text{DPAP})_2$  (2), [2-pyrrolaldehyde-2'-hydroxyanilato(2-)]-2-pyrrolaldehyde-2'-hydroxyanilato-oxo-Re(V)  $\text{ReO}(\text{PAHA})_2$  (3), {4-[1-(N'-benzoylhydrazino)-1-phenyl-methylidene]-3-methyl-1-phenyl-pyrazol-5-onato(2-)}-{4-[1-(N'-benzoylhydrazino)-1-phenyl-methylidene]-3-methyl-1-phenyl-pyrazol-5-onato}-oxo-Re(V)  $\text{ReO}(\text{BHMP})_2$  (5), and for the neutral ligand (BHMP). Re is in a distorted octahedral coordination environment in all complexes with one ligand tridentate in the equatorial plane and the other bidentate in the axial position. The Re-N bond lengths are 2.01-2.18 Å depending on the nature of the bond caused by mesomeric and steric


effects of the ligands. To check the bonding relations, MO calcns. with Gaussian 94 were carried out and force field calcns. were performed using the Extensible Systematic Force Field (ESFF). This was done to examine the ability of the ESFF to represent the bonding relations to provide reasonable input data for MO calcns.

IT 183113-24-8P  
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation, crystal structure and reaction with rhenium oxo complex)  
RN 183113-24-8 CAPLUS  
CN Benzoic acid, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylen]hydrazide (9CI) (CA INDEX NAME)




RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 40 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1999:138079 CAPLUS <<LOGINID::20070702>>  
DN 130:261014  
TI Synthesis, characterization and biological activity of rare earth complexes of 1-phenyl-3-methyl-5-hydroxy-4-pyrazolyl phenyl ketone isonicotinoyl hydrazone  
AU Yang, Zhengyin; Yang, Rudong; Li, Qi; Li, Fashen  
CS Dep. Chem., Lanzhou Univ., Lanzhou, 730000, Peop. Rep. China  
SO Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry (1999), 29(2), 205-214  
CODEN: SRIMCN; ISSN: 0094-5714  
PB Marcel Dekker, Inc.  
DT Journal  
LA English  
AB 1-Phenyl-3-methyl-5-hydroxy-4-pyrazolyl Ph ketone isonicotinoyl hydrazone (H2L), was prepared by condensation of 1-phenyl-3-methyl-4-benzoyl-5-pyrazolone with isoniazid. Seven complexes of rare earths with H2L were synthesized and characterized from elemental analyses, IR, UV, 1H NMR spectra and thermal analyses. The general formula of the complexes is RE(HL)3·3.5 H2O (RE = La3+-Gd3+). The ligand and its complexes of the light rare earth metals possess antioxidative activity and inhibitory action on lipid peroxidn.  
IT 221524-99-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and complexation with rare earth ions and antioxidative activity as hydroxyl radical scavengers and lipid peroxidn. inhibitors)  
RN 221524-99-8 CAPLUS  
CN 4-Pyridinecarboxylic acid, [(2,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylen]hydrazide (9CI) (CA INDEX NAME)




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 41 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1997:375841 CAPLUS <<LOGINID::20070702>>  
 DN 127:75044  
 TI Oxovanadium binuclear (IV) Schiff base complexes derived from aroyl hydrazones having subnormal magnetic moments  
 AU Rao, Sumita N.; Mishra, D. D.; Maurya, R. C.; Rao, N. Nageswara  
 CS Dep. Post Grad. Studies and Res. Chem., Rani Durgavati Vishwavidyalaya, Jabalpur, 482 001, India  
 SO Polyhedron (1997), 16(11), 1825-1829  
 CODEN: PLYHDE; ISSN: 0277-5387  
 PB Elsevier  
 DT Journal  
 LA English  
 AB Oxovanadium(IV) complexes of aroyl hydrazone Schiff bases, viz. salicyloyl, nicotinoyl and benzoyl hydrazones, were synthesized and characterized by elemental anal., spectroscopy (IR and UV-visible) methods, magnetic susceptibility, EPR measurements, molar conductance and cyclic voltammetry studies. The room-temperature magnetic moments of the complexes are in the range 0.97-1.03  $\mu_B$  and are indicative of the presence of antiferromagnetic exchange. A binuclear structure is proposed for the complexes.  
 IT 191219-02-0P 191219-03-1P 191219-04-2P  
 191219-05-3P 191219-06-4P 191219-07-5P  
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (for preparation of vanadyl benzoyl- or nitrobenzoyl(methyl)(phenyl)pyrazolone aroyl hydrazone Schiff base complexes)  
 RN 191219-02-0 CAPLUS  
 CN Benzoic acid, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)




RN 191219-03-1 CAPLUS

CN Benzoic acid, 2-hydroxy-, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



RN 191219-04-2 CAPLUS


CN 4-Pyridinecarboxylic acid, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)






RN 191219-05-3 CAPLUS

CN Benzoic acid, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)(4-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 191219-06-4 CAPLUS

CN Benzoic acid, 2-hydroxy-, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)(4-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 191219-07-5 CAPLUS

CN 4-Pyridinecarboxylic acid, [(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)(4-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 42 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1997:218200 CAPLUS <<LOGINID::20070702>>  
DN 126:271404  
TI Tin(IV) complexes with diacidic azo(hydrazono) compounds. Crystal structure of bis[4-(2'-hydroxyphenylazo)-3-methyl-1-phenylpyrazol-5-onato(2-)]tin(IV)  
AU Bansse, Wolfgang; Jager, Norbert; Ludwig, Eberhard; Schilde, Uwe; Uhlemann, Erhard; Lehmann, Andreas; Mehner, Hartmut  
CS Institut Anorganische Chemie Didaktik Chemie, Univ. Potsdam, Potsdam, D-14415, Germany  
SO Zeitschrift fuer Naturforschung, B: Chemical Sciences (1997), 52(2), 237-242  
CODEN: ZNBSEN; ISSN: 0932-0776  
PB Verlag der Zeitschrift fuer Naturforschung  
DT Journal  
LA German  
AB Sn(IV) complexes of diacidic azo and hydrazono compds. were synthesized by the reaction of these ligands with SnCl<sub>2</sub>acac<sub>2</sub> and SnCl<sub>2</sub>·2H<sub>2</sub>O, resp. The complexes were further characterized by Mossbauer spectroscopy. For bis[4-(2-hydroxyphenylazo)-3-methyl-1-phenylpyrazol-5-onato(2-)]tin(IV), force field calcns. were performed and the crystal structure was determined by x-ray anal. [orthorhombic, Pbcn; a 23.915(15), b 9.196(9), c 13.180(6) Å; V = 2899 Å<sup>3</sup>; Z = 4; R<sub>1</sub> = 0.1701, wR<sub>2</sub> = 0.112].  
IT 183113-24-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(for preparation of tin azo(hydrazono) complexes)  
RN 183113-24-8 CAPLUS  
CN Benzoic acid, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)



✓ #43

L13 ANSWER 43 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1996:628253 CAPLUS <<LOGINID::20070702>>  
 DN 125:315287  
 TI Titanium and vanadium complexes of 4-[1-(N'-benzoylhydrazino)-1-phenylmethylidene]-3-methyl-1-phenylpyrazol-5-one. Crystal structure of 4-[1-(N'-benzoylhydrazino)-1-phenylmethylidene]-3-methyl-1-phenylpyrazol-5-one  
 AU Kraudelt, Heide; Schilde, Uwe; Hefele, Heike; Ludwig, Eberhard; Uhlemann, Erhard  
 CS Institut Anorganische Chemie Didaktik Chemie, Universitaet Potsdam, Potsdam, D-14415, Germany  
 SO Zeitschrift fuer Naturforschung, B: Chemical Sciences (1996), 51(9), 1240-1244  
 CODEN: ZNBSEN; ISSN: 0932-0776  
 PB Verlag der Zeitschrift fuer Naturforschung  
 DT Journal  
 LA German  
 AB By reaction of 1-phenyl-3-methyl-4-benzoylpyrazol-5-one with benzoylhydrazine the tridentate diacidic ligand 4-[1-(N'-benzoylhydrazino)-1-phenylmethylidene]-3-methyl-1-phenylpyrazol-5-one (I; H<sub>2</sub>L) is formed which gives ML<sub>2</sub> (M = Ti, V). The ligand and its complexes were characterized by mass spectroscopy. The V(IV) complex was oxidized and reduced electrochem. The chemical bonding in the Ti(IV) complex and in the ligand was studied by IR and <sup>13</sup>C NMR. The mol. structure of I was determined by x-ray anal. Crystal data: a 9.159(3), b 11.014(4), c 11.136(5) Å, α 90.11(2), β 101.84(3), γ 113.01(2)°; space group P.hivin.1, Z = 2.  
 IT 183113-24-8P  
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and crystal structure and complexation with titanium and vanadium)  
 RN 183113-24-8 CAPLUS  
 CN Benzoic acid, [(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide (9CI) (CA INDEX NAME)




L13 ANSWER 44 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1996:526478 CAPLUS <<LOGINID::20070702>>  
 DN 125:264236  
 TI Synthesis and spectroscopic studies of trinuclear uranyl complexes with compartmental ligands H<sub>4</sub>L derived from 2,6-dipicolinoyl-hydrazine and 4-acyl-1-phenyl-3-methyl-pyrazolones-5 (where acyl = benzoyl, acetyl, iso-butyryl or iso-valeroyl)  
 AU Chen, Xiao-yuan; Zhan, Shu-zhong; Meng, Qing-jin  
 CS Coordination Chemistry Inst., Nanjing University, Nanjing, 210093, Peop. Rep. China  
 SO Transition Metal Chemistry (London) (1996), 21(4), 345-348  
 CODEN: TMCHDN; ISSN: 0340-4285  
 PB Chapman & Hall


DT Journal  
 LA English  
 AB The potentially trinucleating ligands H4L were synthesized in situ by reacting 2,6-dipicolinoylethyldihydrazine with 4-acyl-1-phenyl-3-methyl-pyrazol-5-one (acyl = benzoyl, acetyl, iso-butyryl or iso-valeroyl) in a 1:2 molar ratio. These ligands react with an excess of uranyl acetate dihydrate to yield trinucleating uranyl complexes  $[(UO_2)_3(L)(DMF)_4(OAc)_2] \cdot 5H_2O$ . Tentative structures for the complexes are proposed from elemental analyses, IR and electronic data. The force constant (f) for the  $\nu_{as}(O=U=O)$  vibration and values for the U-O distance, RU-O, are calculated. The spectral studies support the trinuclear structure.

IT 182220-70-8P 182220-72-0P 182220-74-2P  
 182220-76-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (for preparation of uranyl acylpyrazolone dipicolinoylethyldihydrazone compartmental Schiff base trinuclear complexes)

RN 182220-70-8 CAPLUS  
 CN 2,6-Pyridinedicarboxylic acid, bis[[[4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide] (9CI) (CA INDEX NAME)




RN 182220-72-0 CAPLUS  
 CN 2,6-Pyridinedicarboxylic acid, bis[[[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)ethylidene]hydrazide] (9CI) (CA INDEX NAME)




RN 182220-74-2 CAPLUS

CN 2,6-Pyridinedicarboxylic acid, bis[[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)-3-methylbutylidene]hydrazide] (9CI) (CA INDEX NAME)




RN 182220-76-4 CAPLUS


CN 2,6-Pyridinedicarboxylic acid, bis[[1-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)-2-methylpropylidene]hydrazide] (9CI) (CA INDEX NAME)



L13 ANSWER 45 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1996:64171 CAPLUS <<LOGINID::20070702>>  
 DN 124:218523  
 TI Complexes of some platinum Group metals with hydrazone ligands and their catalytic oxidative properties  
 AU El-Hendawy, A. M.; Al-Kubaisi, A. H.; Shoaib, A. F.  
 CS Chemistry Department, University of Qatar, Doha, Qatar  
 SO Monatshefte fuer Chemie (1995), 126(12), 1291-302  
 CODEN: MOCMB7; ISSN: 0026-9247  
 PB Springer  
 DT Journal  
 LA English  
 AB New complexes of Ru(II), Ru(III), Os(III), and Pd(II) were prepared with a neutral bidentate hydrazone ligand derived from antipyrine-4-carboxaldehyde and benzoylhydrazine. Ru(III) complexes were also synthesized from monobasic bidentate ligands prepared from benzaldehyde and benzoyl or para-substituted benzoylhydrazines. The complexes were characterized by spectroscopic techniques and investigated by cyclic voltammetry. The efficient catalytic oxidation of alcs. and 3,5-di-tert-butylcatechol in the presence of N-methylmorpholine-N-oxide or m-chloroperbenzoic acid as cooxidants was reported.  
 IT 76644-54-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (for preparation of platinum-group hydrazone complexes)  
 RN 76644-54-7 CAPLUS  
 CN Benzoic acid, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




L13 ANSWER 46 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1991:440682 CAPLUS <<LOGINID::20070702>>  
 DN 115:40682  
 TI Some lanthanide(III) nitrate complexes of N-(4'-benzoylidene-3'-methyl-1'-phenylpyrazol-5'-one)isonicotinylhydrazine  
 AU Indrasenan, P.; Sarojini, K. R.  
 CS Dep. Chem., Univ. Kerala, Trivandrum, 695 034, India  
 SO Indian Journal of Chemistry, Section A: Inorganic, Bio-inorganic, Physical, Theoretical & Analytical Chemistry (1991), 30A(4), 382-4  
 CODEN: ICACEC; ISSN: 0376-4710  
 DT Journal  
 LA English  
 GI



AB  $\text{Ln}(\text{BMPIH})_2(\text{NO}_3)_3$  (Ln = La, Pr, Nd, Sm, Eu, Gd, Tb, Dy and Y; BMPIH = I). In these complexes BMPIH acts as a neutral bidentate ligand utilizing the azomethine N and the ring carbonyl O as the donor atoms. The nitrate groups coordinate in a unidentate fashion and, hence, a coordination number of 7 is assigned to the central metal ion.  
 IT 134646-18-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
 RN 134646-18-7 CAPLUS  
 CN 4-Pyridinecarboxylic acid, [(2,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenylmethylene]hydrazide, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L13 ANSWER 47 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1991:61995 CAPLUS <<LOGINID::20070702>>  
 DN 114:61995  
 TI Potential antibacterial agents. Part II. Synthesis of substituted N-antipyrinyl methylenebenzohydrazides and 2-antipyrinyl-5-aryl-1,3,4-oxadiazoles  
 AU Begum, Tahira; Hussain, Shaheen A.; Sultana, Naheed; Murtaza, Najma;

Qureshi, Izhar H.

CS PCSIR Lab. Complex, Karachi, Pak.

SO Pakistan Journal of Scientific and Industrial Research (1989), 32(11), 722-5


CODEN: PSIRAA; ISSN: 0030-9885

DT Journal

LA English

OS CASREACT 114:61995

GI



AB Condensation of 4-formylantipyrine with substituted benzohydrazides  $H_2NNHCOR$  ( $R = Ph$ , substituted  $Ph$ ) afforded substituted antipyrinylmethylenbenzohydrazides I. On treatment with bromine-acetic acid-sodium acetate, I ( $R = Ph$ , 4-MeC<sub>6</sub>H<sub>4</sub>, 4-MeOC<sub>6</sub>H<sub>4</sub>, 4-ClC<sub>6</sub>H<sub>4</sub>) readily cyclized to 2-antipyrinyl-5-aryl-1,3,4-oxadiazoles II, whereas I ( $R = 2-HOC_6H_4$ ), under similar treatment furnished the hitherto unreported dibromo compound III. Antibacterial activity of the compds synthesized was also evaluated. They did not show any significant activity.


IT 102017-61-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and bromination of)


RN 102017-61-8 CAPLUS

CN Benzoic acid, 2-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)






IT 76644-54-7P 131536-11-3P 131536-12-4P  
 131536-13-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and sequential bromination and intramol. cyclization of,  
 oxadiazole derivative from)  
 RN 76644-54-7 CAPLUS  
 CN Benzoic acid, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 131536-11-3 CAPLUS  
 CN Benzoic acid, 4-methyl-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI). (CA INDEX NAME)




RN 131536-12-4 CAPLUS

CN Benzoic acid, 4-methoxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 131536-13-5 CAPLUS


CN Benzoic acid, 4-chloro-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 48 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1991:61992 CAPLUS <<LOGINID::20070702>>  
 DN 114:61992  
 TI Synthesis of substituted 2,3-dihydro-1,3,4-oxadiazole derivatives  
 containing a substituted pyrazole moiety as potential anti-inflammatory  
 agents  
 AU Farghaly, Ahmed M.; Chaaban, Ibrahim; El-Khawass, El-Sayed M.; Fahmy,  
 Salwa M.  
 CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt  
 SO Alexandria Journal of Pharmaceutical Sciences (1989), 3(2), 158-60  
 CODEN: AJPSES; ISSN: 1110-1792  
 DT Journal  
 LA English  
 GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Pyrazolecarboxaldehyde benzoylhydrazones I and II (R = H, OH; R1 = H, OH,  
 OMe, NH2, R2 = H, OH) were prepared by the condensation of the corresponding  
 pyrazolecarboxaldehydes with 2,4,5-RR1R2C6H2CONHNH2. Treating I with Ac2O  
 gave pyrazolyloxadiazoles III (R = H, OAc, R1 = H, OAc, OMe, NHAc, R2 = H,  
 OAc).  
 IT 76644-54-7P 102017-61-8P 131536-12-4P  
 131624-93-6P 131624-94-7P 131643-74-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 76644-54-7 CAPLUS  
 CN Benzoic acid, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-  
 yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 102017-61-8 CAPLUS

CN Benzoic acid, 2-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 131536-12-4 CAPLUS

CN Benzoic acid, 4-methoxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 131624-93-6 CAPLUS

CN Benzoic acid, 4-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 131624-94-7 CAPLUS

CN Benzoic acid, 2,5-dihydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 131643-74-8 CAPLUS

CN Benzoic acid, 4-amino-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




L13 ANSWER 49 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1990:425554 CAPLUS <<LOGINID::20070702>>  
 DN 113:25554  
 TI Heterocyclic 1:1 hydrazone-metal complex pigments for organic polymers and coating materials  
 IN Cseh, Georg; Lienhard, Paul; Wiedemann, Walter  
 PA Ciba-Geigy A.-G., Switz.  
 SO Eur. Pat. Appl., 22 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 349489	A2	19900103	EP 1989-810485	19890622
	EP 349489	A3	19911016		
	R: CH, DE, FR, GB, IT, LI				
	US 5066695	A	19911119	US 1989-374321	19890629
	JP 02110145	A	19900423	JP 1989-171022	19890701
PRAI	CH 1988-2514	A	19880701		
OS	MARPAT 113:25554				
GI					



I



II

AB The title pigments are 1:1 I (ring A = carbocyclic or heterocyclic aromatic residue; E = carbocyclic aromatic residue, heterocyclic aromatic residue containing  
 ≥1 N atom; R1 = C1-18 alkyl, carbocyclic aromatic residue, heterocyclic residue containing ≥1 N atom; such that ≥1 of A and

B are a heterocyclic residue containing  $\geq 1$  N atom) transition metal complexes of  $\text{Ni}^{2+}$ ,  $\text{Cu}^{2+}$ ,  $\text{Zn}^{2+}$ ,  $\text{Fe}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Co}^{2+}$ ,  $\text{Cd}^{2+}$ ,  $\text{Pt}^{2+}$ , or  $\text{VO}^{2+}$ , useful for coloring organic polymers, printing inks, and coating materials, are prepared by the condensation of aromatic ketones with aromatic carboxylic acid


hydrazides. Thus, 2-hydroxypropiophenone was condensed with nicotinic acid hydrazide forming hydrazone II which was complexed with  $\text{Ni}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$  to form a yellow 1:1 II-Ni complex.

IT 127868-81-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and complexation of, with divalent transition metal cations)

RN 127868-81-9 CAPLUS

CN 4-Pyridinecarboxylic acid, [1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)ethylidene]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 50 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1989:135625 CAPLUS <<LOGINID::20070702>>

DN 110:135625

TI Heterocycles from carbohydrate precursors: cyclohexylidenation of 1-p-bromophenyl-3-(L-threo-glycerol-1-yl)-2-pyrazoline-4,5-dione 4-(p-bromophenylhydrazone)

AU El-Kilany, Yelde; Mousaad, Ahmed; El-Harbrouk, Mahmoud


CS Fac. Sci., Alexandria Univ., Alexandria, Egypt

SO Arabian Journal for Science and Engineering (1988), 13(3), 427-30  
CODEN: AJSEDY; ISSN: 0377-9211

DT Journal

LA English

GI




I

AB Treatment of the title compound (I; R = H) with cyclohexanone and H<sub>2</sub>SO<sub>4</sub> gave 90% cyclohexylidene derivative (I; R<sub>2</sub> = cyclohexylidene), whose structure was confirmed by combined chemical and spectral methods.

IT 119555-32-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 119555-32-7 CAPLUS

CN Benzoic acid, 4-nitro-, [[1-(4-bromophenyl)-4-[(4-bromophenyl)hydrazono]-4,5-dihydro-5-oxo-1H-pyrazol-3-yl]methylene]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 51 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1988:610940 CAPLUS <<LOGINID::20070702>>

DN 109:210940

TI Synthesis of hydrazones and pyrazolones from dehydro-L-ascorbic acid

AU Atta, K.; Wilde, H.; Hauptmann, S.

CS Sekt. Chem., Karl-Marx-Univ. Leipzig, Leipzig, DDR-7012, Ger. Dem. Rep.


SO Pharmazie (1988), 43(2), 77-9  
 CODEN: PHARAT; ISSN: 0031-7144

DT Journal

LA German

OS CASREACT 109:210940

GI



AB Starting from dehydro-L-ascorbic acid glycerylpyrazolinedione hydrazones I (R = CHOCH<sub>2</sub>CHOHCH<sub>2</sub>OH, R<sub>1</sub> = Cl, NO<sub>2</sub>) were prepared Acetylation, benzylation, and acetylation-bromination of I gave I (R = CHR<sub>2</sub>CHR<sub>2</sub>CH<sub>2</sub>R<sub>3</sub>, R<sub>1</sub> = Cl, NO<sub>2</sub>; R<sub>2</sub> = R<sub>3</sub> = OAc, OBz; R<sub>2</sub> = Br, R<sub>3</sub> = OAc), whereas NaIO<sub>4</sub> oxidation gave I (R = CHO, R<sub>1</sub> = Cl, NO<sub>2</sub>). Some condensation reactions of these products were also reported.


IT 116228-31-0P



RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 116228-31-0 CAPLUS

CN Benzoic acid, [[4,5-dihydro-4-[(2-nitrophenyl)hydrazono]-5-oxo-1-phenyl-1H-pyrazol-3-yl]methylene]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 52 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1981:453955 CAPLUS <<LOGINID::20070702>>

DN 95:53955

TI Complexes of lanthanide perchlorates with two new "O,N,O" ligands derived from antipyralsdehyde and acetic and benzoic acid hydrazides

AU Jagannathan, R.; Soundrarajan, S.

CS Dep. Inorg. Phys. Chem., Indian Inst. Sci., Bangalore, 560 012, India

SO Inorganic and Nuclear Chemistry Letters (1981), 17(3-4), 65-8

CODEN: INUCAF; ISSN: 0020-1650

DT Journal

LA English


AB The preparation of antipyralsdehyde 4-acylhydrazones [acyl = acetyl (L), benzoyl (L')] and their lanthanide complexes are described. L and L' act as tridentate O,N,O-ligands in the 9-coordinate complexes [LnL3](ClO4)3.3H2O (Ln = La, Nd, Yb) and [LnL'3](ClO4)3 (Ln = La, Nd, Y).

IT 76644-54-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 76644-54-7 CAPLUS

CN Benzoic acid, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




L13 ANSWER 53 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1981:95054 CAPLUS <<LOGINID::20070702>>


DN 94:95054

TI Complexes of lanthanide perchlorates with two new "O,N,O" ligands derived




from antipyrinaldehyde and acetic and benzoic acid hydrazides  
 AU Jagannathan, R.; Soundararajan, S.  
 CS Dep. Inorg. Phys. Chem., Indian Inst. Sci., Bangalore, 560 012, India  
 SO Inorganic and Nuclear Chemistry Letters (1980), 16(9-12), 575-82  
 CODEN: INUCAF; ISSN: 0020-1650  
 DT Journal  
 LA English  
 AB Antipyrinaldehyde acetyl- and benzoylhydrazones (L) and their rare earth complexes  $[LnL_3](ClO_4)_3$  were prepared and characterized by chemical anal., electronic, IR, and NMR spectra, and elec. conductivity The ligands are coordinated to Ln via the 2 O atoms and the imine N atom and the complexes are 9-coordinate.  
 IT 76644-54-7DP, rare earth metal complexes 76644-54-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 76644-54-7 CAPLUS  
 CN Benzoic acid, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 76644-54-7 CAPLUS  
 CN Benzoic acid, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 54 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1977:485187 CAPLUS <<LOGINID::20070702>>  
 DN 87:85187  
 TI Heterocycles from carbohydrate precursors. Part IV. Synthesis of some pyrazole derivatives having L-threo and D-erythro side chains  
 AU El Ashry, El Sayed H.; El Kilany, Yeldez; Singab, Farrag  
 CS Fac. Sci., Alexandria Univ., Alexandria, Egypt  
 SO Carbohydrate Research (1977), 56(1), 93-104  
 CODEN: CRBRAT; ISSN: 0008-6215  
 DT Journal  
 LA English  
 OS CASREACT 87:85187  
 GI




AB Rearrangement of I (X = PhNHN; X1 = 4-R2-C6H4NHN; R = OH; R1 = H; R2 = Me, Cl, Br, iodo) gave the pyrazoles II (R3 = Me, Cl, Br, iodo; R4 = R6 = H, R5 = OH). Periodate oxidation of II (R3 = Me, R4 = R6 = H, R5 = OH) gave III (R7 = Me, X2 = O). Similarly, rearrangement of the bis(hydrazones) I (X = X1 = 4-R2C6H4NHN, R = H, R1 = OH, R2 = Cl, Br, iodo) gave the pyrazoles II (R3 = R4 = Cl, Br, iodo, R5 = H, R6 = OH). Periodate oxidation of II (R3 = R4 = R5 = H, R6 = OH) followed by condensation with R8CONHNH2 (R8 = H, Me, Cl, MeO, 4-pyridyl) gave III (R7 = H, X2 = R8CONHN).

IT 63621-80-7P 63621-81-8P 63621-82-9P  
63621-83-0P 63621-84-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 63621-80-7 CAPLUS

CN Benzoic acid, [[4,5-dihydro-5-oxo-1-phenyl-4-(phenylhydrazono)-1H-pyrazol-3-yl]methylene]hydrazide (9CI) (CA INDEX NAME)




RN 63621-81-8 CAPLUS


CN Benzoic acid, 4-methyl-, [[4,5-dihydro-5-oxo-1-phenyl-4-(phenylhydrazono)-1H-pyrazol-3-yl]methylene]hydrazide (9CI) (CA INDEX NAME)




RN 63621-82-9 CAPLUS  
 CN Benzoic acid, 4-methoxy-, [[4,5-dihydro-5-oxo-1-phenyl-4-(phenylhydrazono)-1H-pyrazol-3-yl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 63621-83-0 CAPLUS  
 CN Benzoic acid, 4-chloro-, [[4,5-dihydro-5-oxo-1-phenyl-4-(phenylhydrazono)-1H-pyrazol-3-yl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 63621-84-1 CAPLUS  
 CN 4-Pyridinecarboxylic acid, [[4,5-dihydro-5-oxo-1-phenyl-4-(phenylhydrazono)-1H-pyrazol-3-yl]methylene]hydrazide (9CI) (CA INDEX NAME)



L13 ANSWER 55 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1977:30991 CAPLUS <<LOGINID::20070702>>  
 DN 86:30991  
 TI Bishydrazide metal complexes  
 IN L'Eplattenier, Francois; Vuitel, Laurent  
 PA Ciba-Geigy A.-G., Switz.  
 SO Ger. Offen., 23 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2556405	A1	19760624	DE 1975-2556405	19751215
	CH 606285	A5	19781031	CH 1974-16813	19741217
	US 3988323	A	19761026	US 1975-640374	19751212
	CA 1074786	A1	19800401	CA 1975-241774	19751215
	FR 2295091	A1	19760716	FR 1975-38422	19751216
	JP 51088538	A	19760803	JP 1975-151175	19751217

PRAI CH 1974-16813 A 19741217

GI For diagram(s), see printed CA Issue.

AB Sym. bishydrazides (I, A = benzene, naphthalene, pyridine, quinoline, pyrazole nucleus; Z = phenylene, 2, thiophenediyl; R = H, Ph, Me) were prepared by reaction of Z(CONHNH<sub>2</sub>)<sub>2</sub> with the appropriate hydroxyaryl carbonyl compound, and were subsequently treated with Cu<sup>++</sup>, Ni<sup>++</sup>, Ca<sup>++</sup>, or Cd<sup>++</sup> to give 1:1 or 2:1 complexes useful as pigments for PVC [9002-86-2]. For example, 2,1-HOC<sub>10</sub>H<sub>6</sub>CHO [708-06-5] and p-C<sub>6</sub>H<sub>4</sub>(CONHNH<sub>2</sub>)<sub>2</sub> [136-64-1] in HOAc at 100° gave I (A = naphthalene, R = H) (II) [61255-98-9] in 96% yield; treatment of II with 1 or 2 equivalent Cu(OAc)<sub>2</sub> in Me cellosolve at 100° gave the 1:1 or 2:1 complex in 89-92% yield. Nineteen addnl. I and 34 other metal complexes were also prepared


IT 61255-91-2D, metal complexes

RL: USES (Uses)

(pigments, for PVC)

RN 61255-91-2 CAPLUS

CN 1,3-Benzenedicarboxylic acid, bis[[[4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)methylene]hydrazide] (9CI) (CA INDEX NAME)




IT 61255-90-1P 61255-91-2P

RL: IMF (Industrial manufacture); PREP (Preparation)  
(preparation of)


RN 61255-90-1 CAPLUS

CN 1,4-Benzenedicarboxylic acid, bis[[[4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)methylene]hydrazide] (9CI) (CA INDEX NAME)



RN 61255-91-2 CAPLUS

CN 1,3-Benzenedicarboxylic acid, bis[[[4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)methylene]hydrazide] (9CI) (CA INDEX NAME)



L13 ANSWER 56 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1976:510096 CAPLUS <<LOGINID::20070702>>

DN 85:110096

TI 1:1 Azomethine-metal complex dyes

IN L'Eplattenier, Francois; Vuitel, Laurent

PA Ciba-Geigy A.-G., Switz.

SO Ger. Offen., 24 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2556473	A1	19760701	DE 1975-2556473	19751215
	CH 606284	A5	19781031	CH 1974-16810	19741217
	CA 1070677	A1	19800129	CA 1975-241772	19751215
	FR 2295092	A1	19760716	FR 1975-38423	19751216
	JP 51088539	A	19760803	JP 1975-151176	19751217
	US 4144258	A	19790313	US 1977-840707	19771011
PRAI	CH 1974-16810	A	19741217		
	US 1975-640373	A3	19751212		

GI For diagram(s), see printed CA Issue.


AB Azomethines (I, A = benzene, naphthalene, pyridine, quinoline, benzofuran, pyrimidine, pyrazole residue; B = benzene, naphthalene, quinoline residue) were prepared, isolated, and treated with Cu<sup>2+</sup> and Ni<sup>2+</sup> salts to give yellow to yellow green 1:1 azomethine pigments, useful for coloring plastics. Thus, a mixture of 2-HOC<sub>6</sub>H<sub>4</sub>CONHNH<sub>2</sub> [936-02-7] and 2,1-HOC<sub>10</sub>H<sub>6</sub>CHO [708-06-5] in HOAc were heated at 100° for 2 hr to give I (A = naphthalene, B = benzene residues) [54009-54-0] which was treated with Cu(OAc)<sub>2</sub>·2H<sub>2</sub>O in Me Cellosolve to give 1:1 Cu complex [60265-88-5]. Ni and Cu 1:1 complexes of I were also prepared in a one-pot process.

IT 60256-57-7P


RL: IMF (Industrial manufacture); PREP (Preparation)  
(preparation of)

RN 60256-57-7 CAPLUS

CN 3-Quinolinecarboxylic acid, 1,2-dihydro-4-hydroxy-2-oxo-,  
[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)methylene]hydrazide  
(9CI) (CA INDEX NAME)




L13 ANSWER 57 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1970:31685 CAPLUS <<LOGINID::20070702>>  
 DN 72:31685  
 TI Pyrazoline-5-one and pyrazolidine-3,5-dione derivatives with  
 antiphlogistic and analgesic activity  
 AU Nardi, Dante; Massarani, Elena; Magistretti, M. J.  
 CS Res. Div., Recordati S.a.S., Milan, Italy  
 SO Arzneimittel-Forschung (1969), 19(10), 1721-3  
 CODEN: ARZNAD; ISSN: 0004-4172  
 DT Journal  
 LA English  
 GI For diagram(s), see printed CA Issue.  
 AB The title compds. (I and II) were obtained by condensing primary and  
 secondary amines with 1-phenyl-3-methyl-or, 1,3-diphenyl-4-formylpyrazolin-  
 5-one, or 1,2-diphenyl-4-formylpyrazolidine-3,5-dione. Thus, the  
 following I were prepared (R, R1 and m.p. given): Me, NHC6H4OH-p,  
 272-3°; Me, NHC6H4OMe-p, 167-8°; Me, NHC6H4OEt-p,  
 144-5°; Me, NHC6H4NHAc-p, 213°; Me, NHC6H4CO2Et-p,  
 173°; Me, NHNHCONC5H4, 259-60°; Me, antipyrinylamino,  
 214-15°; Me, pyrrolidino, 171-2°; Me, piperidino,  
 188°; Me, morpholino, 136-7°; Me, N4-methylpiperazino,  
 170°; Me, NHPH, ; Ph, NHC6H4OH-p, 257°; Ph, NHC6H4OMe-p,  
 137-8°; Ph, NHC6H4OEt-p, 130-1°; Ph, NHC6H4NHAc-p,  
 237-9°; Ph, NHC6H4CO2Et-p, 145-7°; Ph, antipyrinylamino,  
 204-5°; Ph, pyrrolidino, 151-2°; Ph, piperidino,  
 168-9°; Ph, morpholino, 186-7°; Ph, N4-methylpiperazino,  
 164-5°; and Ph, NHPH, . II prepd were (R and m.p. given):  
 HNC6H4OH-p, 186-8°; HNC6H4OMe-p, 152-3°; NHC6H4NHAc-p,  
 275°; pyrrolidino, 234-5°; piperidino, 208°;  
 morpholino, 195°; N4-methylpiperazino, 237-8°; NHPH, ;  
 NHC6H4OEt-p, ; NHC6H4CO2Et-p, ; and antipyrinylamino, . Also prepared  
 were III (R, n, m, and m.p. given): Me, 2, 2, 164-5°; Me, 1, 0,  
 238-9°; and Ph, 2, 2, 163°; and IV. The compds. did not  
 show antipyretic activity, but many exhibited a significant  
 antiinflammatory activity.  
 IT 4702-86-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 4702-86-7 CAPLUS  
 CN 4-Pyridinecarboxylic acid, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-  
 pyrazol-4-ylidene)methyl]hydrazide (9CI) (CA INDEX NAME)



✓ #59

L13 ANSWER 58 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1966:447652 CAPLUS <<LOGINID::20070702>>  
 DN 65:47652  
 OREF 65:8891f-g  
 TI Condensation product of chloromethyl antipyrinyl ketone and isoniazid  
 AU Ergenc, Nedime  
 CS Univ. Istanbul  
 SO Istanbul. Univ. Eczacilik Fak. Mecmuasi (1965), 1(1), 82-9  
 DT Journal  
 LA Turkish  
 GI For diagram(s), see printed CA Issue.  
 AB A solution of 0.96 g. isonicotinic acid hydrazide in 1:1 EtOH-H<sub>2</sub>O is heated for 5 min. in a water bath with a solution of 1.85 g. chloromethyl antipyrinyl ketone in PhMe. The orange crystals were washed with CHCl<sub>3</sub> and EtOAc to yield 70% title compound I, m. 180-200° (decomposition). The structure of I was confirmed by Cl determination, by iodometric titration of the hydrazide group, by conversion into the quaternary ammonium iodide, by titration with K<sub>3</sub>Fe(CN)<sub>6</sub>, and by mol. weight determination  
 IT 6822-71-5P, Isonicotinic acid, (1-antipyrinyl-2-chloroethylene)hydrazide  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 6822-71-5 CAPLUS  
 CN Isonicotinic acid, (1-antipyrinyl-2-chloroethylene)hydrazide (7CI, 8CI)  
 (CA INDEX NAME)



L13 ANSWER 59 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1966:27489 CAPLUS <<LOGINID::20070702>>  
 DN 64:27489  
 OREF 64:5065c-g  
 TI Hydrolysis product from 1-phenyl-3-methyl-4-dimethylaminomethylene-5-pyrazolone  
 AU Kvitko, I. Ya.; Porai-Koshits, B. A.  
 SO Zhurnal Obshchei Khimii (1964), 34(9), 3005-13  
 CODEN: ZOKHA4; ISSN: 0044-460X  
 DT Journal  
 LA Russian  
 GI For diagram(s), see printed CA Issue.  
 AB cf. CA 61, 14659e. Hydrolysis of 1-phenyl-3-methyl-4-



dimethylaminomethylene-5-pyrazolone yields the compound which is known as 1-phenyl-3-methyl-4-formyl-5-pyrazolone (I) (Ridi and Checchi, CA 48, 4522c); however, this name is not correct. Our studies indicate pK 2.94, uv maximum 250, 351, and 435 mμ, constant over a wide range of pH. The compound adds 1 mole Br and reacts readily with R1R2NH, SOCl2, HCl, RCOCl, and CH2N2, indicating the presence of an OH group in the 4-position. With azonium chlorides it forms known dyes (CA 42, 369g). Thus, the compound must have the formula Ia. This structure is supported by ir spectra (Snavey, et al., CA 57, 5904c). A series of derivs. of I was synthesized. To 0.5 g. Ia suspended in 5 ml. CHCl3 and cooled to 0° was added dropwise (over 15 min.) 0.4 g. Br in 3 ml. of CHCl3. The reaction mixture was then stirred 30 min. at room temperature, the product precipitated with petr. ether, filtered off, and washed with C6H6 and Et2O to yield apprx. 61% 1-phenyl-3-methyl-4-bromo-4-bromohydroxymethyl-5-pyrazolone, m. 176-9°. Ia (7.0 g.) was suspended in 60 ml. CHCl3, cooled to 0°, and stirred 2 hrs. with dropwise addition of excess SOCl2 in 40 ml. CHCl3, the stirring continued 1 hr., and the mixture concentrated

in vacuo to dryness. The residue was suspended in C6H6, filtered, and the precipitate washed with Et2O to yield 1-phenyl-3-methyl-4-chloromethylene-5-pyrazolone (II), 81%, m. 152-3°. In another method, 0.5 g. Ia was suspended in 10 ml. MeOH, cooled to 0°, saturated with dry HCl until all solid was dissolved, evaporated to dryness, suspended in anhydrous Et2O, filtered, washed with Et2O, and dried to yield II, 85.5%. Ia (0.5 g.) suspended in 20 ml. absolute Et2O, 0.2 g. pyridine, and then dropwise at room temperature 0.35 g. PhCOCl, added, and allowed to stay at room temperature over-night.


The precipitated product was filtered off, washed with H2O until neutral, and dried in a vacuum desiccator to yield 1-phenyl-3-methyl-4-benzoyloxymethylene-5-pyrazolone, 91.5%, m. 112-15°. Attempted recrystallization C6H6 caused decomposition Ia (8.0 g.) in 50 ml. Et2O was cooled to 0° and 60 ml. solution of CH2N2 in Et2O, (obtained from 9.5 g. of nitrosourea) added. After evolution of N ceased, the solvent was removed and the crude product (8.1 g.) distilled at 149-50°/0.5 mm. to yield 3.9 g. 1-phenyl-3-methyl-4-methoxymethylene-5-pyrazolone.

IT 4702-86-7


(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 4702-86-7 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)methyl]hydrazide (9CI) (CA INDEX NAME)




AN 1966:27488 CAPLUS <<LOGINID::20070702>>  
 DN 64:27488  
 OREF 64:5065b-c  
 TI Isothiazoles. X. Some sulfonic acid derivatives  
 AU Pain, D. L.; Parnell, E. W.  
 CS May Baker Ltd., Dagenham, UK  
 SO Journal of the Chemical Society (1965), (Dec.), 7283-84  
 CODEN: JCSOA9; ISSN: 0368-1769  
 DT Journal  
 LA English  
 OS CASREACT 64:27488  
 AB cf. preceding abstract 3-Methylisothiazole- and 5-amino-3-methylisothiazole-4-sulfonic acids have been prepared, and the sulfonyl chloride of the former converted into the amide, anilide, and hydrazide. The sulfonyl chloride was also reduced to give the sulfinic acid, from which 3-methylisothiazole-4-sulfinamide was obtained.  
 IT 4702-86-7  
 (Derived from data in the 7th Collective Formula Index (1962-1966))  
 RN 4702-86-7 CAPLUS  
 CN 4-Pyridinecarboxylic acid, 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)methyl]hydrazide (9CI) (CA INDEX NAME)




L13 ANSWER 61 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1963:419700 CAPLUS <<LOGINID::20070702>>  
 DN 59:19700  
 OREF 59:3515e-f  
 TI Copper complexes with ethylenediamine  
 AU Stankoviansky, I. S.; Rusina, R.; Faithova, E.  
 CS Univ. K., Bratislava, Czech.  
 SO Acts Fac. Rerum Nat. Univ. Comenianae, Chimia (1961), 4, 645-53  
 DT Journal  
 LA Slovak  
 AB In neutral and alkaline aqueous solution  $[\text{Cu(en)}_2]^{++}$  and  $[\text{Cu(en)(H}_2\text{O)}_2]^{++}$  were analyzed polarographically and spectrophotometrically. In alkaline medium,  $[\text{Cu(en)}_2]^{++}$  predominates, but in acidic medium the equilibrium is shifted toward aquo complexes, e.g.,  $[\text{Cu(H}_2\text{O)}_4]^{++}$ . Water is displaced from the complexes by increasing the en concentration Polarographic half-wave potentials of  $[\text{Cu(en)}_2]^{++}$  and  $[\text{Cu(en)(H}_2\text{O)}_2]^{++}$  were determined  
 IT 101721-56-6P, Isonicotinic acid, (antipyrinylmethylene)hydrazide, Cu complex  
 RL: PREP (Preparation)


(preparation of)  
 RN 101721-56-6 CAPLUS  
 CN Isonicotinic acid, (antipyrinylmethylene)hydrazide (6CI) (CA INDEX NAME)



L13 ANSWER 62 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1960:68904 CAPLUS <<LOGINID::20070702>>  
 DN 54:68904  
 OREF 54:13267e-f  
 TI The amine oxides of biologically active compounds. IV. The bacteriostatic action in vitro of amine oxides of isonicotinic and nicotinic acid derivatives  
 AU Porebska, Alicja; Zemburowa, Krystyna; Gorczyca, Maria  
 CS Acad. Med. Krakow, Krakow, Pol.  
 SO Dissertationes Pharmaceuticae (1959), 11, 315-20  
 CODEN: DIPHAH; ISSN: 0301-1615  
 DT Journal  
 LA Unavailable  
 AB cf. CA 52, 6337h. The in vitro bacteriostatic action (special reference to tuberculostatic action) of derivs. of the N-oxide of isonicotinic acid and nicotinic acid of the types hydrazones with aldehydes and ketones and acyl- or aryl-thiosemicarbazides is much weaker than that of the parent substances.  
 IT 101721-58-8  
 (Derived from data in the 6th Collective Formula Index (1957-1961))  
 RN 101721-58-8 CAPLUS  
 CN Isonicotinic acid, (antipyrinylmethylene)hydrazide, 1-oxide (6CI) (CA INDEX NAME)



L13 ANSWER 63 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1960:68903 CAPLUS <<LOGINID::20070702>>  
 DN 54:68903  
 OREF 54:13267c-e  
 TI Fractionation of the system bringing about oxidative phosphorylation in  
 Azotobacter vinelandii  
 AU Hovenkamp, H. G.  
 CS Univ. Amsterdam  
 SO Nature (London, United Kingdom) (1959), 184(Suppl. No. 7), 471  
 CODEN: NATUAS; ISSN: 0028-0836  
 DT Journal  
 LA Unavailable  
 AB cf. CA 53, 20271f. Centrifugation at 50,000 g for 30 min. fractionated a  
 suspension of particles from A. vinelandii reversibly inactivated as to  
 respiratory phosphorylation by exposure to lowered salt concns.  
 Restoration of this activity by adding back salts required preincubation  
 of the sediment, which contained 85-90% of the reduced diphosphopyridine  
 nucleotide oxidase activity, with the supernatant and 0.008M MgCl<sub>2</sub>. The  
 restorative factor in the supernatant was destroyed by heating at  
 100° for 5 min.  
 IT 101721-58-8  
 (Derived from data in the 6th Collective Formula Index (1957-1961))  
 RN 101721-58-8 CAPLUS  
 CN Isonicotinic acid, (antipyrinylmethylene)hydrazide, 1-oxide (6CI) (CA  
 INDEX NAME)



L13 ANSWER 64 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1959:105580 CAPLUS <<LOGINID::20070702>>

DN 53:105580

OREF 53:18966i,18967a

TI 4-Formylantipyrine isonicotinylhydrazone

IN Nitta, Yoshihiro; Shiota, Jitsuho


PA Chugai Drug Manufg. Co.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 33005732	B4	19580730	JP	
AB	4-Formylantipyrine (21.6 g.) and 14 g. 4-H <sub>2</sub> NNHCOC <sub>5</sub> H <sub>4</sub> N in 150 ml. EtOH were refluxed 30 min. and the solution cooled to give 30 g. title compound, needles, m. 249-50°. The product showed growth inhibition of Mycobacterium tuberculosis (human type) at the dilution of 1:640,000-1:1,280,000.				
IT	101721-56-6P, Hydrazine, 1-(antipyrinylmethylene)-2-isonicotinoyl-				
RL	PREP (Preparation) (preparation of)				
RN	101721-56-6 CAPLUS				
CN	Isonicotinic acid, (antipyrinylmethylene)hydrazide (6CI) (CA INDEX NAME)				



L13 ANSWER 65 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1959:105579 CAPLUS <<LOGINID::20070702>>

DN 53:105579

OREF 53:18966h-i

TI Mixed citrate

IN Kallischnigg, Rolf; Leube, Erwin


PA Knoll A.-G. Chemische Fabriken

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1008295		19570516	DE 1954-K21537	19540319
AB	4-(N-Phenylbenzylamino)-1-methylpiperidine (28 g.), 15.5 g. 1-cyclohexyl-2-methylaminopropane, and 21.2 g. citric acid monohydrate was dissolved in 150 cc. warm Me <sub>2</sub> CO and the resulting salt allowed to crystallize to give a nearly quant. yield of the corresponding citrate C <sub>19</sub> H <sub>24</sub> N <sub>2</sub> .C <sub>10</sub> H <sub>21</sub> N.C <sub>6</sub> H <sub>8</sub> O <sub>7</sub> , m. 88-90°, which exhibits synergistic activity to antihistaminics.				
IT	101721-56-6P, Antipyrinaldehyde, isonicotinoylhydrazone				
	RL: PREP (Preparation)				
	(preparation of)				
RN	101721-56-6 CAPLUS				
CN	Isonicotinic acid, (antipyrinylmethylene)hydrazide (6CI) (CA INDEX NAME)				



L13 ANSWER 66 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1957:85704 CAPLUS <<LOGINID::20070702>>

DN 51:85704

OREF 51:15512i,15513a-f

TI The Michael addition of 2-picolyl-2-ketones

AU Beyer, Hans; Lassig, Wolfgang; Schudy, Gerhard

CS Univ. Greifswald, Germany

SO Chemische Berichte (1957), 90, 592-8

CODEN: CHBEAM; ISSN: 0009-2940

DT Journal

LA Unavailable

OS CASREACT 51:85704

AB The reaction of 2-pyridylacetone (I), 2-phenacylpyridine (II), and deoxypyridoin (III) with acrylonitrile (IV), MeCOCH:CH<sub>2</sub> (V), and PhCH:CHCOME (VI) has been studied. In general, IV, V, or VI in EtOH is added to I, II, or III in 10-20 cc. absolute EtOH containing a few platelets of KOH at below 60° and, after the initial reaction has subsided, the mixture is heated 5 min. on an H<sub>2</sub>O bath. The reaction mixture of 58 g. I and 24 g. IV is poured into 5 times its volume of H<sub>2</sub>O, 9 g. γ-(2-pyridyl)-2-γ-acetylpyimelic acid dinitrile (VII) filtered off, the filtrate acidified, washed with Et<sub>2</sub>O, made alkaline, and extracted with Et<sub>2</sub>O or CHCl<sub>3</sub>, and

the residue of the dried extract distilled, giving 44.5% γ-(2-pyridyl)γ-acetylbutyric nitrile (VIII), b<sub>15</sub> 188-92°, m. 34°; it gives a blue-green color with FeCl<sub>3</sub> [phenylhydrazone (PH), needles, m. 180.5-1° (decomposition); picrate, shiny yellow leaflets, m. 124-5° (decomposition)]. Similarly, 15 g. I and 32 g. IV yield 82% VII, needles, m. 111.5°; 9.4 g. VIII and 5.3 g. IV give 85% VII (PH, small rods, m. 161°; picrate, stout yellow columns, m. 134° (decomposition)). Refluxing 1.9 g. VIII 0.5 hr. with 6 cc. concentrated H<sub>2</sub>SO<sub>4</sub>, diluting

the mixture with 50 cc. H<sub>2</sub>O, neutralizing it with Na<sub>2</sub>CO<sub>3</sub>, and extracting with CHCl<sub>3</sub> give 83.5% γ-(2-pyridyl)γ-acetylbutyric acid (IX), clusters of crystals, m. 121°. Adding dropwise 5.3 g. IV in 10 cc. absolute EtOH to 23.3 g. II.HCl and 8 g. KOH in 30 cc. absolute EtOH, adding


H<sub>2</sub>O, and extracting with Et<sub>2</sub>O yield 48% γ-Bz analog of VIII, rhombic plates, m. 75°, which, saponified, gives 89% Bz analog (X) of IX, rhombic leaflets, m. 134-5° (PH, m. 161°). Boiling 1.35 g. X with 2.8 g. KOH in 2 cc. H<sub>2</sub>O until colorless, neutralizing the mixture with 50 cc. N HCl, filtering off the BzOH, and extracting the residue of the evaporated

filtrate with C6H6 yield 79%  $\gamma$ -(2-pyridyl)butyric acid, m. 85°. Treating 4 g. III with 2.1 g. IV gives 51%  $\gamma$ -(2-pyridyl) $\gamma$ -(2-pyridoyl)butyric acid nitrile, stout rhombs, m. 72°, which, saponified, yields 90% free acid, needles or leaflets, m. 108°. Treating 27 g. I with 18 cc. V gives 3-methyl-6-(2-pyridyl)-2-cyclohexen-1-one (XI), b12 154°; it gives a blue-green color with FeCl3 [PH, needles, m. 151-2° (decomposition); picrate, rhombic yellow leaflets, m. 111-12° (decomposition)]. Heating 7.5 g. XI with 2 g. S 45 min. at 180°, extracting the mixture with Et2O, and distilling the residue of the extract yield 34% 3-methyl-6-(2-pyridyl)phenol, b2 155-60°, needles, m. 50°; it gives a blue-violet color with FeCl3 [picrate, stout rhombic needles, m. 197° (decomposition)]. Treating 9.5 g. I with 14.5 g. VI yields 77% 3,5-diphenyl-6-(2-pyridyl)-2-cyclohexen-1-one (XII), shiny orange-yellow leaflets, m. 152°; green color with FeCl3 [picrate, long yellow needles, m. 184° (decomposition); di-Br addition compound, prepared with Br-AcOH in AcOH, needles, m. 206-7°]. Heating 1.6 g. XII and 1 g. Se 2-3 hrs. at 200-50°, extracting the melt with EtOH, and concentrating the extract give 44% 3,5-diphenyl-6-(2-pyridyl)phenol, yellowish needles, m. 157.5°, violet color with FeCl3. Treating 4.6 g. II.HCl with 1.5 g. KOH and 1.5 g. V and extracting the mixture with Et2O yield 5-(2-pyridyl)-5-benzoyl-2-pentanone, needles, m. 166°. Similarly, 4 g. III and 3.5 g. V give 65% 5-(2-pyridyl)-5-(2-pyridoyl)-2-pentanone, rhombs, m. 151°; 11.7 g. II.HCl and 5 g. KOH in 50 cc. EtOH and 10.4 g. VI in 50 cc. EtOH yield 69%  $\beta$ -phenyl- $\gamma$ -(2-pyridyl)- $\gamma$ -benzoylbutyrophenone, needles, m. 188°; 3.2 g. III and 3.35 g. VI give 71%  $\beta$ -phenyl- $\gamma$ -(2-pyridyl)- $\gamma$ -(2-pyridoyl)butyrophenone, needles, m. 196-7°.

IT 102002-34-6P, Hydrazine, 1-(1-antipyrinylolethylidene)-2-(3,5-dibromosalicyloyl)-  
 RL: PREP (Preparation)  
 (preparation of)


RN 102002-34-6 CAPLUS

CN Salicylic acid, 3,5-dibromo-, (1-antipyrinylolethylidene)hydrazide (6CI)  
 (CA INDEX NAME)






OREF 51:15512g-i  
 TI Synthesis of tuberculostatic compounds. V. Synthesis of some new hydrazones of salicylic acid hydrazide and 3,5-dibromosalicylic acid hydrazide  
 AU Klosa, Josef  
 CS ASAL Sci. Lab., Berlin  
 SO Arch. Pharm. (1955), 288, 49-52  
 DT Journal  
 LA Unavailable  
 AB cf. C.A. 51, 8086b, 14690f. The following new hydrazones of salicylic acid hydrazide were prepared (reactant and m.p. given): anisaldehyde, 218-19°; salicylaldehyde, 274-6°; cinnamaldehyde, 237°; vanillin, 215°; crotonaldehyde, 190-2°; furfural, 225-7°; antipyrinaldehyde, 214-16°; Me<sub>2</sub>CO, 231-2°; EtCOMe, 150°; cyclohexanone, 212-13° (decomposition); PhAc, 208-10° (decomposition); acetylantipyrine, 295°. The following new hydrazones of 3,5-dibromosalicylic acid hydrazide were prepared (reactant and m.p. given): BzH, 236°; anisaldehyde, 238°; salicylaldehyde, 200°; cinnamaldehyde, -; vanillin, 220°; furfural, 232°; antipyrinaldehyde, 242°; Me<sub>2</sub>CO, 204°; cyclohexanone, 182°; 4-acetylantipyrine, 228°. All compds. showed slight in vitro tuberculostatic activity.  
 IT 101868-30-8P, Hydrazine, 1-(antipyrinylmethylene)-2-(3,5-dibromosalicyloyl)- 102002-34-6P, Hydrazine, 1-(1-antipyrinylethylidene)-2-(3,5-dibromosalicyloyl)- 102017-61-8P, Hydrazine, 1-(antipyrinylmethylene)-2-salicyloyl- 102157-96-0P, Hydrazine, 1-(1-antipyrinylethylidene)-2-salicyloyl-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 101868-30-8 CAPLUS  
 CN Benzoic acid, 3,5-dibromo-2-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 102002-34-6 CAPLUS  
 CN Salicylic acid, 3,5-dibromo-, (1-antipyrinylethylidene)hydrazide (6CI)  
 (CA INDEX NAME)




RN 102017-61-8 CAPLUS

CN Benzoic acid, 2-hydroxy-, [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 102157-96-0 CAPLUS

CN Salicylic acid, (1-antipyrinylylethylidene)hydrazide (6CI) (CA INDEX NAME)



L13 ANSWER 68 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1957:81463 CAPLUS <<LOGINID::20070702>>

DN 51:81463

OREF 51:14721b-f

TI Aminooxides of physiologically active compounds. I. Aminooxides of isonicotinic acid derivatives

AU Eckstein, Marian; Gorczyca, Marian; Kocwa, Aleksander

CS Zaklad Chem. Farm. Akad. Med., Krakow

SO Dissertationes Pharmaceuticae (1956), 8, 239-47

CODEN: DIPHAH; ISSN: 0301-1615

DT Journal

LA Unavailable

AB N-oxide (10 g.) of isonicotinic acid (prepared according to Ghigi, C.A. 37, 47346) crystallized from MeOH, m. 264-6°, dissolved in 200 ml. anhydrous alc., refluxed 2-3 (3-6) hrs. with chlorhydrate or concentrated H<sub>2</sub>SO<sub>4</sub>, made basic with Na<sub>2</sub>CO<sub>3</sub>, extracted with 100 ml. CCl<sub>4</sub>, dried over anhydrous K<sub>2</sub>CO<sub>3</sub>, and recrystd. from C<sub>6</sub>H<sub>6</sub> yielded a crystalline mass (I), m. 65-9°. A .01M solution I treated with 1.3 ml. H<sub>2</sub>NNH<sub>2</sub>.H<sub>2</sub>O, heated 5 min. on H<sub>2</sub>O bath, cooled, 5 ml. EtOH added, filtered off, and recrystd. from EtOH gave N-oxide of isonicotinic acid hydrazide (II), m. 219° which had a LD<sub>50</sub> of 1675 mg./kg. for mice (20-25 mg.) when injected intraperitoneally. The aldehydes of II prepared in MeOH or EtOH included (compound given): cinnamic acid, m. 244° [from 90% EtOH (III)]; 2-nitrocinnamic acid, m. 277° [from boiling H<sub>2</sub>O and EtOH (IV)]; 2-hydroxybenzoic acid, m. 272° (from III); 4-hydroxybenzoic acid, m. 288-90° (from IV); 4-methoxybenzoic acid, m. 255° (from III); 2-nitrobenzoic acid, m. 296-7° (from IV); 3-nitrobenzoic acid, m. 284-5° (from IV); 4-nitrobenzoic acid, m. 274-6° (from IV); 4-chlorobenzoic acid, m. 279-80° (from III); 2-carboxybenzoic acid, m. 203-4° (anhydrous) [from 50% EtOH] (V) and; m. 170° (containing H<sub>2</sub>O of crystallization); 4-acetylaminobenzoic acid, m. 291-2° (from III); 4-dimethylaminobenzoic acid, m. 238-9° (from 90% EtOH); 2-hydroxy-5-bromobenzoic acid, m. 282-3° (from AcOH and H<sub>2</sub>O); 3-methoxy-4-hydroxybenzoic acid, m. 285-7° (from AcOH); 2,3-dimethoxybenzoic acid, m. 254-5° (from AcOH); 2,5-dimethoxybenzoic acid, m. 236-7° (from III); 3,4-methyl-enodioxibenzoic acid, m. 268-9° (from III); 1-naphthoic acid, m. 258-9° (from III); 2-hydroxy-1-naphthoic acid m. 285-6° (from IV); 2-ethoxy-1-naphthoic acid, m. 227-8° (from V); furfural, m. 243-4° (from 96% MeOH); 4-formylantipyrine, m. 270-1° (from V); the ketone derivative included iso-BuCOMe, m.

167-9° (from 90% MeOH); the diacetyl, m. 308-10° (from H2O).


28 references.

IT 101721-58-8

(Derived from data in the 6th Collective Formula Index (1957-1961))

RN 101721-58-8 CAPLUS

CN Isonicotinic acid, (antipyrinylmethylene)hydrazide, 1-oxide (6CI) (CA INDEX NAME)



L13 ANSWER 69 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1956:74061 CAPLUS <<LOGINID::20070702>>

DN 50:74061

OREF 50:13939g-i,13940a-c

TI Syntheses of pyrazolone derivatives. I. Synthesis of 4-formylantipyrine and some of its reactions

AU Ito, Isao

CS Nagoya City Univ.

SO Yakugaku Zasshi (1956), 76, 167-9

CODEN: YKKZAJ; ISSN: 0031-6903

DT Journal

LA Unavailable

AB HCONMe<sub>2</sub> (14.6 g.) and 37.6 g. antipyrine (I) at 0° treated with 33.75 g. POCl<sub>3</sub>, heated 3 hrs. on a water bath, and the product decomposed with ice water, made alkaline with NaHCO<sub>3</sub>, and extracted with CHCl<sub>3</sub> gave 28.1

g.

4-formylantipyrine, (II), columns, m. 162°. HCONMePh (2.7 g.), 3.76 g. I, and 3.27 g. POCl<sub>3</sub> heated 3 hrs. on a water bath and the product treated as above gave 2.3 g. II. II (1.08 g.) and 1.04 g. CH<sub>2</sub>(CO<sub>2</sub>H)<sub>2</sub> in 3 ml. C<sub>5</sub>H<sub>5</sub>N and 3 drops of piperidine heated 8 hrs. at 130°, the product acidified with HCl, filtered, washed with Et<sub>2</sub>O, and recrystd. from 50% EtOH gave 0.52 g. β-(4-antipyrinyl)acrylic acid, needles, m. 210-1° (decomposition). MeNO<sub>2</sub> (4 g.), 0.12 g. MeNH<sub>2</sub>.HCl, 0.048 g. Na<sub>2</sub>CO<sub>3</sub>, and 4 ml. EtOH let stand 3 days at 0° and the product filtered gave 1.1 g. 4-(2-nitrovinyl)antipyrine, granules, m. 160-60.5°. II (1.08 g.), 0.96 g. BzNHCH<sub>2</sub>CO<sub>2</sub>H, 0.4 g. AcONa, and 1.5 g. Ac<sub>2</sub>O heated 2 hrs. on a water bath, heated with EtOH, the solution filtered and the filtrate cooled gave 0.9 g. 2-phenyl-4-antipyrinylmethylene-5-oxazolone, needles, m. 224° (decomposition). II (0.54 g.), 0.34 g. dioxopiperazine, 0.32 g. fused AcONa, and 0.5 g. Ac<sub>2</sub>O heated 8 hrs. at


140°, the product in hot EtOH filtered and recrystd. from EtOH gave 0.51 g. 3-(4-antipyrinylmethylene)-2,5-piperazinedione, leaves, m. 263-4° (from EtOH). I (2.16 g.), 0.91 g. H<sub>2</sub>NNHCSNH<sub>2</sub>, and 50% EtOH heated 2 hrs. on a water bath gave 2.7 g. II thiosemicarbazone, plates, m. 229° (decomposition). 4-H<sub>2</sub>NHNOCC<sub>5</sub>H<sub>4</sub>N(2.16g.), 3 drops piperidine, and 15 ml. EtOH heated 3 hrs. on a water bath gave 3.1 g. II isonicotinyldiazide, needles, m. 263° (decomposition). Me antipyrinate (5 g.), 2.3 g. 65% N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O, and 3 drops piperidine heated 2 hrs. on a water bath gave 4.2 g. antipyrinic acid hydrazide (III), columns, m. 200-1°. III (1.23 g.), 1.08 g. II, 10 ml. EtOH, and 3 drops piperidine heated 6 hrs. on a water bath gave 1.8 g. antipyrinic acid antipyrinylmethylenediazide, granules, m. 232-3°. II (1.08 g.), 0.12 g. NaCN, and 5 ml. 5% EtOH heated 3 hrs. on a bath gave 0.3 g. insol. 4-(β-antipyrinylacryloyl)-1-phenyl-2-methyl-5-pyrazolone, prisms (IVa), m. 258°, and the mother liquor gave 0.05 g. 4-acetyl-1-phenyl-2-methyl-5-pyrazolone (IV), needles, m. 218°. II (5 g.) in 15 ml. 5% NaOH heated 2 hrs. on a water bath, allowed to stand overnight, and the product filtered gave 4.1 g. IV and 0.28 g. hot water-insol. IVa, m. 258°. IV(1 g.), 0.5 g. BzH, and 5 ml. 5% NaOH heated at 60° gave 4-cinnamoyl-1-phenyl-2-methyl-5-pyrazolone, granules, m. 234° (decomposition).

IT 101721-56-6P, Isonicotinic acid, (antipyrinylmethylene)hydrazide  
858209-36-6P, Hydrazine, 1-(antipyrinylmethylene)-2-antipyroyl-  
RL: PREP (Preparation)

(preparation of)


RN 101721-56-6 CAPLUS

CN Isonicotinic acid, (antipyrinylmethylene)hydrazide (6CI) (CA INDEX NAME)



RN 858209-36-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



L13 ANSWER 70 OF 70 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1956:1514 CAPLUS <<LOGINID::20070702>>  
 DN 50:1514  
 OREF 50:329c-e  
 TI Several isonicotinylhydrazones  
 AU Efimovsky, Olga; Rumpf, Paul  
 SO Bulletin de la Societe Chimique de France (1954) 1401-4  
 CODEN: BSCFAS; ISSN: 0037-8968  
 DT Journal  
 LA Unavailable  
 OS CASREACT 50:1514  
 AB Condensation of isonicotinic hydrazide (I) with equimolar quantities of the following resp. carbonyl compds. gave the following isonicotinoylhydrazones (I) (parent carbonyl compound and m.p. of I given): citral, 134°; 2-methyl-4-hydroxy-5-isopropylbenzaldehyde, 253°; 1-phenyl-2,3-dimethyl-4-formyl-5-pyrazolone, 270.5°; 5,5-dimethyl-1,3-cyclohexanedione (C14H17N2O2), 252°; p-O2NC6H4COMe, 291° (281-2° given by Sah and Peoples, C.A. 48, 13789b); 2,5-HO(Cl)C6H3CHO, 245° (232° given by Buu-Hoi, et al., C.A. 48, 7580b); 3,4-MeO(HO)C6H3CHO 231° (219-20° given by Shchukina, et al., C.A. 46, 10431h); p-HOC6H4CHO, 297°. Condensation of I with pyruvic acid gave a product, m. 227° (decomposition) which after drying at 80° for several hrs. in vacuo underwent alteration according to elemental anal. Prepns. were described for aspartic acid dihydrazide, m. 179-80° (135° given by Curtius and Jansen, C.A. 12, 1770) and the monohydrazide, m.p. 182°. The compds. were examined for tuberculostatic activity.  
 IT 101721-56-6P, Hydrazine, 1-(antipyrinylmethylene)-2-isonicotinoyl-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 101721-56-6 CAPLUS  
 CN Isonicotinic acid, (antipyrinylmethylene)hydrazide (6CI) (CA INDEX NAME)

